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ABSTRACT 
 
 
The purpose of this study was to create time-related centile ranges that could be 
used as benchmarks for evaluating and monitoring quality of life (QoL) following kidney 
transplantation.  QoL is commonly viewed as an important indicator of successful 
outcomes in chronic disease including kidney transplantation. Despite extensive research 
documenting the value of QoL, routine measurement of QoL outcomes in clinical 
practice as a means of patient evaluation to augment clinical care has not been widely 
accepted. Lack of benchmarks for interpreting QoL scores may contribute to the 
reluctance to incorporate QoL measures into clinical care. The research question and 
study aim were: Do QoL outcomes differ for patients by gender and race at four separate 
time intervals following renal transplantation? Based on this analysis which demographic 
groups or combination of groups would be required to accurately represent QoL 
outcomes through time-related centile ranges?   
 
A convenience sample was drawn from the surveys housed by the national Patient 
Outcomes Registry for Transplant Effects on Life (PORTEL).  To be included in the 
study, surveys must have been completed by Caucasian or African American recipients 
of one kidney transplantation who were between 18 and 65 years of age and who were 
greater than 14 days post-transplant. SF-12 and Memphis Survey scores were extracted as 
the QoL measures for creation of time-related centile ranges. Data were analyzed using 
nonparametric statistical methods. Time-related centile ranges were constructed depicting 
the 5th through the 95th percentile scores on the QoL outcome measures. 
 
The analysis included 943 surveys bracketed into four time groups, less than 4 
months, 4 to 19 months, 19-36 months and greater that 36 months from transplantation. 
Kruskal-Wallis analyses demonstrated a strong degree of homogeneity among racial and 
gender groups with only 2 of 16 QoL outcome measures differing significantly; SF-12 
PCS scores at 19-36 months and Memphis Frequency scores at less than 4 months. 
Variation in means across the groups was small and the centile ranges were large leading 
to the conclusion that negligible clinical differences exist for these QoL outcomes by 
racial and gender subgroups in this sample.  Therefore, one time-related centile range was 
constructed for each QoL outcome measure for this cohort of kidney transplant recipients 
which will be graphically presented.   
 
These time-related centile ranges have immediate clinical utility as a tool for 
educating patients regarding QoL expectations and for monitoring post transplant QoL 
outcomes. They can also provide a means for transplant recipients to compare their QoL 
to a reference range that is derived from a like population and serve as a catalyst for 
discussion regarding interventions to enhance QoL for kidney transplant recipients. 
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CHAPTER 1. INTRODUCTION 
 
 
Extraordinary advancements in science achieved in the 20th century have changed 
the view of and expectations for health, disease, and treatment of disease. New treatments 
and technology allow individuals to survive for many years with conditions that 
previously would have been fatal such as end-stage renal disease (ESRD).  Renal 
replacement therapy (RRT), peritoneal dialysis or hemodialysis; and transplantation have 
led to long term survival for individuals with ESRD.  Kidney transplantation has not only 
prolonged life, but in addition it has been shown to improve quality of life (QoL) for 
many individuals as well (Dew et al., 1997; Ogutmen et al., 2006; Overbeck et al., 2005). 
However, while transplantation and the immunosuppressant therapy that is required to 
prevent rejection make survival possible with a better QoL, patients continue to have 
health related issues following transplantation. Ongoing treatments, including intensive 
medication regimens, often lead to compromises in health or functional ability that can 
impact QoL (Winsett et al., 2004). With improved patient and graft survival, attention to, 
and evaluation of, QoL in transplant recipients is an important part of ongoing care, as 
well as the assessment of graft and patient survival. 
 
 
Problem Statement 
 
As individuals contemplate whether they should undergo a treatment such as 
organ transplantation in order to improve their health care outcomes, they seek 
information regarding the typical recovery pattern displayed by individuals who are like 
them. Health care providers also look at patterns of response in groups of patients to 
recommend treatment plans based on the risks and benefits of the treatments in question.  
The knowledge gained through examining patterns of recovery can assist the patient in 
determining whether their progress or their health status is typical for an individual in a 
similar situation at a particular point in time. This type of information is often a key 
factor in making initial treatment decisions as well as in the planning of care to facilitate 
recovery. QoL has become an important outcome used by patients and health care 
providers alike for evaluating the effectiveness of treatment regimens for chronic disease 
(Carr, Gibson, & Robinson, 2001; Sullivan, 2003). Understanding QoL outcomes may be 
particularly important for the individual contemplating kidney transplantation since in 
many cases alternative therapy (i.e. hemodialysis or peritoneal dialysis) is available. The 
choice to undergo transplantation is seen as a means to improve QoL as opposed to the 
only treatment means available for survival. Although kidney transplantation has been 
shown in multiple studies to improve QoL (Cameron, Whiteside, Katz, & Devins, 2000; 
Dew et al., 1997), individuals who have undergone kidney transplantation want to know 
how their post-transplantation quality of life compares to others at the same point in their 
recovery; yet this information is not available.  
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Purpose of the Study 
 
The overwhelming number of articles published each year that focus on QoL is 
testimony to the growing interest in the QoL associated with the treatment of chronic 
disease.  In spite of the tremendous interest in QoL in the field of kidney transplantation 
and the numerous reports documenting improvement in QoL following transplantation, 
construction of a trajectory that maps the typical progression in QoL after transplantation 
has not been reported.  Therefore, the purpose of this study will be to construct time-
related centile ranges that depict the progressive changes in QoL that occur following 
kidney transplantation. 
  
 
Study Aims 
 
This descriptive study established time-related centile reference ranges to report 
QoL outcomes in such a way that clinicians and patients can evaluate the QoL of 
individuals and compare it with others who have similar demographic characteristics. The 
time-related centile ranges were constructed from data collected through the Patient 
Outcomes Registry for Transplant Effects on Life (PORTEL), which conducted surveys 
of transplant recipients from 2000-2005. The QoL outcome measures drawn from the 
PORTEL Survey for creation of time-related centile ranges included the physical and 
mental component summary scores from the 12-Item Short Form Health Survey (SF-12) 
and the frequency and severity scores from the Memphis Survey, a measure of 
immunosuppressant related side effects. The study progressed in two stages guided by the 
research question and a study aim. Stage 1 was directed by the research question and 
identified how the study population should be grouped to address the study aim during 
stage 2 of the study which involved generation of the centile ranges. The research 
question (1) and study aim (2) are as follows: 
 
1. Do QoL outcomes differ within groups of patients categorized by gender and 
race? If so then: 
a) Do the QoL outcome measures for patients grouped by gender and 
race differ at four specific time intervals following transplantation? 
b) Which of the variables or combination of variables (gender and race) 
identify cohorts of patients most appropriate for creation of time-
related centile ranges used to illustrate QoL outcomes? 
 
2. Individual time-related centile ranges were established for scores on the SF-12 
and the Memphis Survey for each patient group identified in stage 1. The QoL 
measures included separate scores for the: 
a) SF-12: 
i. Physical Component Summary (PCS) 
ii. Mental Component Summary (MCS) 
b) Memphis Survey scores:  
i. Frequency score how often side effects occur) 
ii. Severity score (level of distress caused by the side effects) 
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Background and Significance 
 
The health related literature is replete with references to QoL. Though the concept 
is has been defined in many ways the definitions are often ambiguous (Meeberg, 1993). 
According to Hathaway, et al. (2003a),  QoL is “broadly accepted to be a 
multidimensional construct that represents an individual’s perception of his or her health, 
happiness, and general well-being at any given period of time” (p. 1). Other authors have 
differentiated the general term QoL from the concept of health related QoL including the 
physical, psychological, and social domains of health in the definition (Pinson et al., 
2000; Testa & Simonson, 1996). QoL has also been defined in such a way that it reflects 
the individual’s functional ability, their perception of their health and well being, and 
their emotional health (Cetingok, Winsett, & Hathaway, 2004). Many factors beyond 
disease influence QoL including overall health and social status (Cetingok et al., 2004). 
 
There has been a shift in the emphasis of the health care industry from focusing 
primarily on curing disease to focusing on controlling disease while enhancing QoL and 
utilizing QoL as a measure of success in the treatment of disease (Yildirim, 2006). In the 
past, the goal of health care as an industry was on treatment to cure disease, or palliative 
care when curative treatment was not an option. Advances in therapeutics have led to 
changes in the delivery of health care, and diseases that would have once been fatal, are 
now regarded as chronic conditions with patients leading long and productive lives.  As a 
result of this transition, the goal of treatment for patients with chronic illness is 
increasingly aimed at controlling disease and maintaining QoL.  
 
Side effects associated with treatment for both acute and chronic disease present 
challenges for health care providers as well as the patient. As opposed to palliating 
symptoms of disease, interventions often involve palliation of the side effects of the 
treatment regimen (Holley, 2007). Assessment of the QoL that a patient experiences on a 
day to day basis, as they live with their disease and the treatment of their disease, can 
guide health care providers in recognizing patient’s needs and formulating a plan of care 
to meet those needs. The use of QoL outcome measurements in nontransplantation 
clinical settings have been shown to enhance communication between the patient and the 
health care provider about QoL issues such as social functioning or symptoms that might 
be otherwise left unaddressed (Detmar, Muller, Schornagel, Wever, & Aaronson, 2002).  
 
An individual’s expectation of their QoL at a given time in life or in relation to a 
given illness can influence the perception of their QoL (Carr et al., 2001).  It is in this 
context that patients who are contemplating transplantation; or who are post 
transplantation seek information regarding the QoL they can anticipate or how their 
actual QoL compares with that of other transplant recipients. Studies have examined both 
short- and long-term QoL post transplantation, and several instruments have been 
developed and validated to measure QoL. However, routine use of QoL outcome 
measurement in the clinical setting has not been widely implemented (Higginson & Carr, 
2001). There are no established norms for QoL post kidney transplantation that can be 
used for providing education or for evaluating recovery. Benchmarks that reflect the QoL 
of kidney transplant recipients could provide an additional tool in the clinical 
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armamentarium to augment post transplantation care. These benchmarks would provide 
normative data for use in educating patients regarding QoL post transplantation and help 
reconcile their post-transplantation QoL with those reported by other transplant 
recipients.  
 
This study creates time-related centile ranges from QoL data collected through the 
Patient Outcomes Registry for Transplant Effects on Life (PORTEL) that could be used 
in the clinical setting as benchmarks for evaluation of QoL outcomes of individual 
patients. These ranges provide clinical tools for education, evaluation, and identification 
of individuals at risk for poor QoL and enabling pre-emptive interventions to improve 
their QoL outcomes. 
 
  
PORTEL Registry 
 
The Patient Outcomes Registry for Transplant Effects on Life (PORTEL) is a 
national data registry that was established by Fujisawa Pharmaceuticals in 2000 to 
document various aspects of the QoL of solid organ transplant recipients. The goals of 
the PORTEL registry included the collection of longitudinal data following solid organ 
transplantation, documenting of the side effects of immunosuppressive therapy, and 
identifying predictors of QoL post transplantation with the intent of using the data to 
establish norms for QoL following transplantation (Hathaway, Winsett, Prendergast, & 
Subaiya, 2003). The PORTEL survey instrument was based on a QoL framework 
composed of 5 interrelated domains that included QoL, health and social factors and, 
major health and major life events (Hathaway, et al., 2003b) that influence both the 
physical and psychosocial aspects of QoL. This framework provides direction for the 
examination of QoL and exploration of the concept in this population.  
 
 
The PORTEL Registry Four-Cornered Framework 
 
The QoL that an individual experiences is related to health and social factors, as 
well as major health and life events. “Factors” (health and social) are conceptualized to 
reflect those circumstances or conditions that, though they may fluctuate to some degree 
over time, remain relatively stable. As these factors reach an optimal state and stabilize, 
post transplantation QoL is enhanced. “Events” (health and life) are conceptualized to 
reflect more acute and transient circumstances or conditions that may negatively impact 
QoL. These “events” and “factors” interact with one another to moderate each of their 
relative influences on QoL, which in turn influences adaptation to and coping with the 
health and social factors and major life and major health events that are a part of the 
transplant recipient’s life  (Hathaway et al., 2003b).  
 
Health factors include comorbidities that were present prior to transplantation, or 
developed subsequent to transplantation, requiring ongoing therapy; or that occured 
following transplantation as a result of side effects from immunosuppressant therapy 
(Hathaway, et al., 2003b). Social factors include situations and events that define an 
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individual’s social environment including the financial resources available to the 
individual, their health care coverage and the social support available to the transplant 
recipient (Hathaway et al., 2003b). Health and social factors influence QoL, as well as 
each other, and the health and life events that the individual encounters. 
 
While health factors and social factors may determine an individual’s day to day 
routine, the ability to cope with them is effected by the major health and life events that 
occur episodically throughout life. Major health events, according to Hathaway, et al. 
(2003b), may be related to a major change in the individual’s health, such as a rejection 
episode. A major health event could also be a fracture secondary to osteoporosis related 
to immunosuppressant therapy or a cardiac event. Major health events could be life 
threatening, a threat to the function of the graft, or a threat to the individual’s ability to 
function or live independently. 
 
Major life events, as with major health events, are those events which also occur 
periodically, disrupting the established routine of the individual or the family (Hathaway, 
et al., 2003b). A major life event as defined in the PORTEL framework may be a divorce, 
death in the family, or loss of a job. Major life and health events influence the perception 
of QoL and health and social factors. 
  
 
Time-Related Centile Ranges 
 
Reference ranges, often referred to as normal ranges, have long been used in health 
care to evaluate the health status of individual patients, on some specific parameter, by 
comparing a variable to a standard for that variable established from a healthy population. 
The range of normal for a given variable is typically defined as the range of values for 
that variable in the population of interest that fall between the 2.5th and the 97.5th 
percentile (Griffiths, Iles, Koduah, & Nix, 2004).  A basic assumption must be that the 
population from which the reference range is derived is representative of “typical” 
individuals and therefore the values for that variable in that population are considered to 
be the normal range. The variables that are reported in a reference range are often 
affected by other characteristics of the representative population (Wright & Royston, 
1997). When this is the case, a single reference range is inadequate. Time is an example 
of such a covariate that can affect the outcome of interest (Cole & Green, 1992). The age 
of the individual at the time of measurement or the amount of time that has elapsed since 
an event has occurred can have a significant influence on the mean and standard 
deviation of a given measurement, therefore reference intervals are commonly 
established with age or time as a covariate (Royston & Wright, 1998). A common 
example of a reference range established to follow change in a variable over time is the 
series of ranges that have been established to monitor the rate of human growth. Growth 
charts are routinely used by health care providers to evaluate the growth of children over 
time. These charts are used to identify those children who are not growing at the 
anticipated rate or who have not achieved the desired height or weight for their age. The 
time-related centile ranges for QoL outcomes of kidney transplant recipients proposed in 
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this study could be used in a similar manner to follow QoL outcomes over time as well 
asevaluating QoL at a particular point in time. 
 
 
Summary 
 
The PORTEL Four-corner framework provided the conceptual underpinnings for 
this investigation. It provided direction for the consideration of QoL outcomes, the 
factors and events that influence these outcomes, and potential avenues for interventions 
to enhance QoL when it is less than what is perceived to be “normal.” The PORTEL 
framework was merged with the analytical perspective of time-related centile ranges to 
provide a mechanism by which to establish a normal range for QoL outcomes 
measurements for transplant recipients, enabling patients and providers to make informed 
decisions regarding treatment, including initiation of new disease management therapy or 
health promotion to improve QoL (Figure 1.1). QoL can change over time as the factors 
and events that influence it change, therefore, continued follow up with periodic 
evaluation is important for long term well being. 
 
 
Operational Definitions   
 
 
Quality of Life 
 
Defining QoL requires integration of objective and subjective domains (Testa & 
Simonson, 1996) that include objective measurements of the individual’s physical health, 
their perception of their health, and their overall sense of well being. Health and life 
events or factors effect the individual’s perception of their QoL as well as their ability to 
function. For purposes of this study, QoL is considered to be a multidimensional concept 
reflected by the following domains and measures. 
 
 
Mental QoL. Mental QoL refers to the individual’s perception of their well-being 
and ability to function in their social roles as measured by the MCS Score of the SF-12. 
The SF-12 includes questions concerning vitality, social functioning, role-emotional 
functioning, and mental health (Ware, Kosinski, & Keller, 1996). 
 
 
Physical QoL. Physical quality of life includes the individual’s objective health 
indicators as well as their perception of their physical health. The PCS score on the SF-
12, was used as the measure of physical QoL, and incorporates physical functioning, role 
functioning, pain, and general health (Ware et al., 1996).  
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Events 
Marriage/Divorce 
Family Deaths 
Job Changes 
Re-evaluate 
Health 
Factors 
Organ 
Function 
Comorbidities 
Side Effects  
Social Factors 
Financial 
Resources 
 Health 
Coverage Social 
SupportQuality of 
Life 
Physical  
Function  
Mental  
Function 
Re-evaluate 
QoL 
Measurement 
and 
Comparison 
with Time-
Related 
Centile Range 
Reassurance 
“Like” 
Others 
Interventions 
to Improve 
QoL 
Figure 1.1.  Conceptual Model of QoL Domains as Defined by the PORTEL Framework 
with the Integration of QoL Outcome Measurement and Time-Related Centile Ranges.   
Adapted with permission. Hathaway, D., Barr, M. L., Ghobrial, R. M., Rodrigue, J., 
Bogner, S., Prendergast, M. M., et al. (2003b). The PORTEL registry: Overview and 
selected findings. Progress in Transplantation, Supplement, 3-13.
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Immunosuppressant Side Effects 
 
The multiple side effects that can result from immunosuppressive therapy have a 
marked impact on QoL and are defined by, and measured, using the Memphis Survey. 
This is a disease specific tool designed to assess the impact of side effects on QoL based 
on their frequency and severity; specifically related to emotional burden, life/role 
responsibilities, mobility, gastrointestinal distress, and miscellaneous side effects 
including gingival hypertrophy, increased hunger, somnolence, weight gain, increased 
hair growth, infections, trembling hands, high blood pressure, easy bruising, decreased 
libido and sexual performance (Winsett et al., 2004). 
 
 
Time-Related Centile Range 
 
Time-related centile ranges plot a value for a variable against a covariate such as 
time. The ranges established provide an estimation of the value of a variable that the 
majority of a population exhibit at a given time and is considered to be a norm for the 
population. Time-related centile ranges have been used for evaluation of a patient’s 
current status or to monitor changes in the variable over time. In this study the covariate 
of interest was the time that has elapsed since kidney transplantation and the variable of 
interest was QoL as measured by the SF-12 and the Memphis Survey. Values from these 
instruments were used to create time-related centile ranges that provided benchmarks for 
QoL following kidney transplantation. 
 
 
Assumptions  
 
The framework of this study was grounded on the following assumptions:  
 
1. Improvement in QoL is desired by individuals.  
2. Expected QoL outcomes play a key role in decisions regarding whether to 
undergo kidney transplantation or continue with alternative methods of kidney 
replacement therapy.  
3. Patients and providers use normal values to benchmark patient progress.  
4. QoL is multi-dimensional composed of physical and mental functions that 
influence and are influenced by health and social factors and major life and 
health events.  
5. QoL is dynamic and can be influenced positively and negatively by external 
conditions and circumstances, some of which are modifiable or can be 
accommodated. 
6. The survey was self-administered and returned to the registry via mail or 
internet, therefore an assumption related to the nature of the study was that the 
survey was completed by the individual and not a family member or friend. 
 
 
 8 
 
Limitations 
 
The following limitations were considered during the conduct of, and in 
interpreting the outcomes of, this study: 
 
1. QoL is an individually perceived phenomenon and may or may not reflect the 
actual health and well being of the individual. However, by definition QoL is 
the individual’s self perception, therefore, regardless of how one compares 
their status with a “normal” benchmark, it is the patient’s perception of their 
QoL that determines successful outcomes. 
2. The patient’s desire to be “normal” as they have previously defined it may not 
be a realistic, or achievable, goal given the complexity of personal, social, & 
health factors and events that surround kidney transplantation. Regardless, 
time-related centile ranges provide valuable comparison data. This vast array 
of potential combinations of personal, social and health factors and events 
precludes establishing centile ranges for all the conceivable combinations, 
therefore application and use must be done with caution. 
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CHAPTER 2. LITERATURE REVIEW 
 
 
QoL has been well established as an important concept in society as well as for 
health care. Pais-Riberio (2004) stated that measurement of QoL dates to President 
Eisenhower’s Commission on National Goals published in 1960. There have been 
literally hundreds of articles from all over the world published on QoL in kidney 
transplantation alone. It is well accepted that kidney transplantation has led to improved 
QoL as compared to hemodialysis or peritoneal dialysis (Dew, et al., 1997), however 
little has been done that translates that knowledge for use in direct patient care. Tools 
providing benchmarks for comparison of the QoL outcomes of an individual patient to a 
large population of kidney transplant recipients would augment the interpretation of QoL 
measures in the clinical setting and enhance patient assessment. The purpose this 
manuscript is to discuss the elements that lead toward the next step in addressing QoL of 
kidney transplant recipients, that is bringing the measurement of QoL to the practice 
arena.  
 
Chronic disease, including renal disease, presents special challenges for patients 
in attaining their desired QoL and for health care providers as they attempt to measure 
and monitor their patients’ QoL.  Yet the desire to address these challenges grows as 
patients and providers seek interventions to improve QoL and methods by which they can 
document the success of these interventions.  Much has been learned from numerous 
clinical trials about how to measure QoL at various stages of disease and from different 
patient populations.  However, little has been done that addresses how QoL assessments 
could be used to evaluate the individual patient’s progress, to identify patients who could 
benefit from interventions designed to improve QoL, to help patients evaluate their own 
QoL in relationship to others with similar characteristics, or to inform patients and 
providers about reasonable QOL expectations on an individual basis. Using QoL 
measures to inform patient care brings QoL assessment from the research arena to the 
bedside. This paper will discuss the changes in chronic illness, particularly renal disease, 
that have made attention to the assessment of QoL a primary focus for patient care, 
present an overview of findings from extant research, and make recommendations for the 
practical application of transplantation-related QOL knowledge that has accumulated 
over the last several decades. 
 
 
The Changing Face of Chronic Illness 
 
The incidence of chronic disease has increased over the course of the last century. 
The primary cause of death at the beginning of the last century was infectious disease but 
by the beginning of the 21st century the leading cause of death had changed and chronic 
diseases such as heart disease, stroke, and cancer had become the most common causes of 
death (Healthy people, 2001). Newer and more effective treatment modalities for both 
acute and chronic illnesses have led to long term survival for many individuals with 
conditions that would have previously been fatal, contributing to the increase in the 
number of individuals who are living with chronic conditions (Ironside et al., 2003). With 
 10 
 
this increase in the prevalence of chronic and often disabling conditions, the focus of 
health care has expanded to encompass not only quantity but quality of life with attention 
to rehabilitation and health promotion for individuals with disabling disease as a primary 
goal (Brandt & Pope, 1997).  
 
Chronic conditions, by definition, are of long duration if not life-long (Bury, 
1991). The goal of treatment is not to achieve cure of disease, but rather control of the 
progression and symptoms of disease. Improved coping and enhancement or maintenance 
of function becomes the goals in planning and implementing care (Cluff, 1981). With this 
shift from cure of disease to disease control as the focus of therapy, QoL becomes a 
common factor that brings together a variety of issues that influence an individual’s well-
being and can be used to determine the effectiveness of therapy (Musschenga, 1997).  
Thus, QoL and the impact of disease and treatment on QoL, have been recognized as 
priorities in planning and implementing health care (Moons, 2004). 
  
 
Quality of Life: The Key Outcome in Chronic Disease 
 
Incorporation of patient centered QoL outcomes as desirable indicators of the 
efficacy of health care is causing a paradigmatic shift, where the focus of care and care 
planning is the patient not the disease (Carr & Higginson, 2001). This paradigm shift can 
have particular significance for the patient who is dealing with a long-term chronic 
condition, and the chosen or required treatment, as well as the disease itself, can impact 
QoL. Moreover, because the patient is dealing with a long-term condition their 
relationship with the health care community will be ongoing. The diagnosis of a chronic 
condition can have a dramatic impact on an individual’s life and role function.  The 
manner in which they adapt to and cope with chronic illness will influence the way in 
which an individual lives their life and hence perceives the quality of the life they are 
living (Corbin & Strauss, 1992) 
 
The attributes that define QoL for a person or family are varied, steeped in their 
values and cultural traditions. The individual’s perception of QoL is determined by the 
interaction of their expectation of what QoL should be and their experience related to 
wellness, illness, and functional ability (Carr, Gibson, & Robinson, 2001). Two patients 
in similar settings with similar conditions may perceive their QoL differently depending 
on their life experiences and expectations regarding QoL, illness, and the interaction of 
the two. Studies have attempted to describe patients’ perceptions of their diseases and 
implications for QoL and have demonstrated that attitudes toward chronic illness and the 
perceptions of chronic illness have changed over time. Thorne and Patterson (1998), in a 
meta-study examining the roles of clients with chronic disease through two decades of 
qualitative research found that the perceptions of patients had evolved from a 
predominantly negative theme of suffering and loss during the 1980’s to a more positive 
perception with themes such as reshaping or reconstituting self, finding meaning, and 
regaining control. They postulate that this transition in perception may in part contribute 
to a shift in the viewpoints of health care providers and patients from one of the client as 
patient to the client as partner. Assuming a partnership role in planning care, 
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reconstituting, reshaping, and regaining control implies an active role taken by patients in 
disease and lifestyle management, and includes seeking information and self evaluation 
as integral to that role. QoL outcome measures used in the clinical setting as assessment 
tools for patients and providers can be a beneficial adjunct as patients evaluate their QoL 
and how it compares with others. 
  
 
Trajectories in Chronic Illness and Kidney Transplantation 
 
Corbin and Strauss (1992) in their nursing model for chronic illness conceptualize 
the course of chronic illness as a multiphase trajectory that changes over time. The 
trajectory of chronic illness, and the associated QoL changes that may follow when one is 
diagnosed with a chronic illness, reflect not only the physiologic qualities of the illness 
but all aspects of the patient’s life and that of their family (Corbin & Strauss, 1992). The 
experience of chronic illness requires a shift in expectation from the anticipated pre-
illness life trajectory to one of life with a chronic illness that incorporates the changes 
that occur as a result of the chronic illness or accompanying disability. Within this shift is 
the added reality that a chronic illness is not a static but a dynamic state, influenced by 
multiple aspects of life and changing with time and disease progression (Joachim & 
Acorn, 2000). The ultimate goal in addressing the changing trajectory of a chronic illness 
is improving or maintaining the QoL of the patient and family. Chronic illness 
trajectories are individual; however, certain aspects of the trajectory can be anticipated 
and guidance can be provided that influences the trajectory at particular points in time 
(Corbin & Strauss, 1992).  Ponton et al., (2001) identified variation in QoL outcome 
measurements after kidney transplantation over time. QoL in the immediate post 
transplantation period was rated as high, with a decrease in perceived QoL during the 7 to 
36 month period after transplantation; followed by improvement as the time from 
transplantation subsequently increased. The variation in QoL may be related to social or 
health factors that intervene over time, including adjustment to the reality that post 
transplantation, patients continue to have health issues consisting of medication side 
effects, complications, and psychosocial issues (Ponton et al., 2001). Assessment of QoL 
in chronic illness and the changes in QoL that occur is an ongoing process that requires 
continued attention and follow-up in order to identify points at which intervention to 
improve QoL might be beneficial. 
 
The desire to be normal or to achieve normalcy in life in the face of chronic 
disease is associated with QoL by patients in studies focusing on coping and adaptation in 
chronic illness (Bradford, 1991; McGrath, Paton, & Huff, 2005; Obrecht, Gallo, & Knafl, 
1992; Snethen, Broome, Bartels, & Warady, 2001). Chronic illness, including kidney 
transplantation may require that an individual redefine what they consider to be normal in 
terms of their QoL as they adapt to their individual chronic illness trajectory. Failure to 
make such a redefinition can lead to feelings of ongoing frustration and failure (Baines, 
Joseph, & Jindal, 2002). Redefining normal requires that the individual reevaluate their 
potential, and develop an understanding of the limitations that may become challenges in 
adapting to life following kidney transplantation. Benchmarks that establish references 
for QoL following kidney transplantation may help transplant recipients in the transition 
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to a new normal by reframing their pre-illness expectations for QoL with a more realistic 
view of their capabilities. Comparison of QoL with that of other transplant recipients to 
determine whether their QoL is comparable to, better than, or worse than the QoL that 
other transplant recipients are experiencing would provide a reference point for 
evaluating their current status.  Support groups provide a similar function and have been 
shown to relieve some of the anxiety associated with chronic illness when individuals 
find that their feelings and experiences are not unique to themselves but are shared by 
others and are a product of their situation (Mechanic, 1977). Seeking information, 
whether it is from health care providers or others who have had the same or similar 
experiences, aides in coping with and in adaptation to chronic disease (Craig & Edwards, 
1983).  
 
 
Defining Quality of Life 
 
Although, the importance of QoL for individuals in evaluating health care 
outcomes is well established, a widely accepted definition of QoL has been elusive 
making agreement as to how it should be measured difficult (Haas, 1999; Meeberg, 
1993). QoL is generally viewed as a multidimensional term representing both subjective 
and objective domains (Testa & Simonson, 1996). The general concept of QoL has been 
differentiated from that of health related QoL with physical, psychological, and social 
domains of health included in the definition (Pinson et al., 2000). QoL has also been 
defined in such a way that it reflects the individual’s functional ability, health and well 
being, and psycho-emotional health (Cetingok, Winsett, & Hathaway, 2004). Many 
factors beyond the impact of disease influence QoL including overall health status and 
social status (Cetingok et al., 2004).  
 
The developers of the Patient Outcomes Registry for Transplant Effects on Life 
(PORTEL) have developed a framework for describing QoL following solid organ 
transplantation which includes 5 separate but interrelated domains (Hathaway et al., 
2003b). The domains include health and social factors, major life and health events, and 
QoL. Health factors are those health related issues that the transplant recipient deals with 
on a daily basis, such as the quality of organ function, co-morbidity that can lead to 
disability including diabetes or osteoporosis, side effects of immunosuppressant agents, 
or health behaviors that can promote or impair health. Social factors are the daily issues 
that shape social functioning, such as, economic support, health care coverage, or 
available social support. Major life and major health events are episodic in nature, but can 
have a significant effect on QoL and daily functioning. Major life events could include 
loss of a job, death of a family member, a marriage or divorce in the family. Major health 
events could include graft loss, a serious infection or other adverse event, or 
hospitalization. The fifth domain in this model is QoL. While QoL can be viewed as a 
separate entity, it is influenced by, and influences the other four domains (Hathaway et 
al., 2003b). Figure 1.1 depicts a model adapted from the PORTEL QoL framework that 
incorporates the use of outcomes based on the original framework as benchmarks for  
comparison of the patient’s QoL with that of others from a similar comparison group. 
Comparing one’s QoL with a similar group can be reassuring as transplant recipients 
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recognize that their QoL is similar to, or exceeds, standard benchmarks. Use of 
benchmarks can also identify individuals who, with intervention, could experience 
enhanced QoL. The dynamic nature of QoL can also be captured when QoL is 
reevaluated over time to monitor a patient’s progress. With improved patient and graft 
survival following kidney transplantation, long term follow-up will require continued 
reassessment of QoL outcomes as aging influences health and social factors, and life and 
health events occur. 
 
 
Quality of Life in Kidney Transplantation 
 
Many studies have demonstrated that kidney transplantation improves QoL 
compared to hemodialysis or peritoneal dialysis (Fujisawa et al., 2000; Lazzaretti, 
Carvalho, Mulinari, & Rasia, 2004; Molzahn, 1991; Niu & Li, 2005; Ogutmen et al., 
2006; Ostrowski, Wesolowski, Makar, & Bohatyrewicz, 2000; Overbeck et al., 2005).  
Liem, Bosch, Arends, Heijunbrok-Kal & Hunink (2007) in a meta-analyses of 52 studies 
that used the SF-36 to compare the QoL of transplantation, hemodialysis, and peritoneal 
dialysis patients, found that following kidney transplantation, patients had better QoL 
than patients receiving hemodialysis or peritoneal dialysis as renal replacement therapy. 
While the majority of studies reported that kidney transplantation improved QoL, there 
have also been studies which found no differences in QoL scores between 
transplantation, hemodialysis, and peritoneal dialysis patients (Sayin, Mutluay, & Sindel, 
2007).  
 
When QoL post transplantation is compared to that of the general population the 
results have been mixed. QoL after kidney transplantation has been reported as similar to 
the QoL of the general population on subjective indicators including role performance, 
social functioning, role limitations due to emotional function, and mental health (Evans et 
al., 1985; Neipp et al., 2006; Rebollo et al., 2000). In other studies, QoL following kidney 
transplantation was improved over other means of kidney replacement therapy but it did 
not equal that of the general population (Dew et al., 1997; Overbeck et al., 2005). Older 
transplant recipients, over 55 years of age, have scored higher on general health 
perception than younger recipients, possibly because older patients are better able to cope 
with changes and limitations that occur with age (Noohi, Karami, Lorgard-Dezfuli-Nejad, 
Najafi, & Saadat, 2007). With this variation in mind, benchmarks specific to QoL post 
kidney transplantation would provide more accurate and realistic comparisons for 
patients and health care providers to use in assessing QoL than benchmarks from general 
population data.    
 
 
Predictors of Quality of Life in Kidney Transplantation 
 
While the majority of studies have found that the QoL of transplant recipients 
overall is superior to the QoL of patients receiving other types of renal replacement 
therapy, there are subgroups of transplant recipients who have not experienced 
improvement in QoL following transplantation. In an attempt to identify those individuals 
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at risk for poorer QoL several studies have identified various health and social factors 
that are predictive of QoL post kidney transplantation. Rosenberger et al. (2006) used the 
term perceived health status (PHS) in lieu of QoL in a study designed to explore the 
predictors of PHS. They found that the predictors of PHS changed over time, with social 
support and lower creatinine predictive of higher PHS in younger patients, and fewer 
hospitalizations and absence of diabetes mellitus predictive of higher PHS in older 
patients. Lower stress related to adverse effects was shown to predict PHS across all 
groups. Following transplantation, side effects of immunosuppressant therapy can replace 
the symptoms associated with chronic renal failure as a source of patient distress that 
compromises QoL (Habwe, 2006).  Khedmat et. al (2007) found poorer QoL to be 
associated with lower education levels, being single or widowed, and the presence of 
diabetes or hypertension. Morbidity during the first six months post transplantation (as 
reflected by the number of days hospitalized), employment, and social support were 
identified as predictors of decreased QoL by Hathaway, et al. (1998). Employment after 
transplantation, viewed as a measure of returning to social functioning, has been 
correlated with better QoL (Matas et al., 2002; Matas et al., 1996). Neipp et al. (2006) 
also found social factors, including employment and social support to be an important 
predictor of better QoL for transplant recipients. The inter-relationships among various 
predictors of post transplantation QoL is supported by findings that demonstrate that the 
presence of comorbidities, the type of transplantation (cadaveric or living donor), age and 
time since transplantation are correlated with participation in social activities such as 
employment, education, and performance of household tasks (van der Mei et al., 2006); 
both are sets of variables which have been found to be associated with post 
transplantation QoL as noted above. 
 
QoL in end stage renal disease has been studied for decades. It has been clearly 
shown that kidney transplantation improves Qol for many patients, but not all, and the 
desire for better QoL drives the decision for many to undergo kidney transplantation 
(Shah et al., 2006). It is also apparent that there is variability in QoL outcomes and that 
QoL appears to have some degree of change over time following transplantation (Ponton 
et al., 2001). In spite of the intense interest in QoL and in measurement of QoL, it has 
been primarily a tool used in the research setting and has not been readily translated into 
the clinical setting for use in patient evaluation (Higginson & Carr, 2001). The variability 
in QoL outcomes and the many health and social factors that have been identified as 
predictors of QoL imply that assessment of the perceived QoL of kidney transplant 
recipients in the clinical setting would be beneficial in identifying those patients at risk 
for less than optimal QoL. 
 
 
Quality of Life Measurement as a Tool in the Clinical Setting 
 
There is general agreement that discussion of QoL between patients and health 
care providers is beneficial, however few studies have demonstrated that measuring QoL 
outcomes change clinical decision making or the patient’s clinical outcomes 
(Espallargues, Valderas, & Alonso, 2000; Greenhalgh, Long, & Flynn, 2005, Levine & 
Ganz, 2002). Measuring QoL in routine practice has, however, been demonstrated to 
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increase communication between patients and providers (Detmar, Muller, Schornagel, 
Wever, & Aaronson, 2002) leading to increased discussion of nonspecific symptoms and 
better QoL and emotional functioning for patients without prolonging the patient 
encounters (Velikova et al., 2004). Although most studies using QoL instruments to 
assess patient outcomes did not find a change in the clinical decision making process; 
increased communication was reported to be benficial in patient care. Higginson & Carr 
(2001) cite five potential uses for QoL measures in the clinical setting directly related to 
clinical care or the evaluation of care; including prioritizing problems, facilitating 
communication, screening for potential problems, identifying preferences of patients, 
monitoring changes or responses to treatments, and training new staff. While QoL 
measures do not substitute for physiologic evaluation of disease; they do capture the 
personal and social context of the patient and put the patient at the forefront of the 
encounter.  
 
Detmar, Muller, Schornagel, Wever, and Aaronson (2000) found that patients 
were willing to discuss QoL with their health care provider. In a sample of patients in 
oncology practice, it was found that patients were very willing to discuss their physical 
and emotional function; but while the patient felt comfortable initiating the discussion of 
physical function, they expected that the provider would initiate any discussion of 
emotional function including social and family issues. Providers on the other hand, in this 
case physicians, tended to discuss emotional issues if the topic was initiated by the 
patient. The authors concluded that this discrepancy as to who should take the lead in 
discussion of psychosocial issues may decrease the likelihood that the discussion will 
take place. Systematic clinical assessment of QoL would provide a catalyst for initiation 
of conversation about social or emotional factors and QoL issues. 
 
In order for QoL measures to become a part of clinical evaluation, barriers to the 
use of QoL instruments must be addressed. In a study that examined the attitudes toward 
the use of health outcome questionnaires in clinical practice Meadows, Rogers, and 
Greene (1998) found that physicians in general practice and nurses expressed a positive 
attitude about using health outcome measurements but were not sure how they would use 
the data in patient care. Other identified barriers to the use of QoL outcome measures 
include time and resource constraints, the perception that available instruments were 
inadequate to measure outcomes, and the belief that QoL outcome measurements were 
unnecessary (Morris, Perez, & McNoe, 1998). Familiarity with QoL questionnaires and 
their use was associated with a more positive attitude toward incorporating them into 
clinical practice in a sample of providers in a pediatric clinical practice (Baars, van der 
Pal, Koopman, & Wit, 2004). A review of trials that assessed the influence of QoL 
outcome measures on clinical decision-making noted that education regarding the 
administration and interpretation of QoL measurement tools, presentation of results in a 
usable format, and implementation in a manner reflecting the process of clinical decision-
making would be helpful in overcoming barriers to using QoL measures in the clinical 
setting (Greenhalgh et al., 2005). Benchmarks for QoL post transplantation based on 
aggregate data, and presented in an easily interpretable format could provide tools that 
would make the use of QoL outcome measures a beneficial part of patient assessment. 
These tools would be used to evaluate the patient’s current QoL, alert the patient and 
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provider to changes in QoL that have occurred, and identify points in the patient’s 
recovery trajectory where strategies or interventions for improving QoL could be 
implemented.  
 
 
Centile Ranges to Interpret Quality of Life 
 
 If QoL outcome measurement is to be useful in the clinical setting, then tools that 
aid in interpreting the values will be helpful for patients and providers. The establishment 
of a range of QoL outcome measurement scores that are typical for patients at particular 
points in time post transplantation would present the data in such a way that it has greater 
utility in the clinical setting.  Reference ranges, often referred to as normal ranges for 
measurements, have long been used in health care to evaluate the health status of patients. 
The range of normal for a particular variable is typically defined as the area between the 
2.5th and the 97.5th percentiles (Griffiths, Iles, Koduah, & Nix, 2004).  The assumption is 
made that the reference population in which the variable is measured is a population 
representative of “normal” or “healthy” individuals, thus the term normal range. The 
simple reference range is inadequate for evaluation when the variable in question is 
strongly dependent on a covariate such as time (Cole & Green, 1992). The tools 
established to document human growth and the references used to monitor bone density 
are common examples of reference ranges that have been established to follow change in 
a variable over time. Development of time-related centile ranges for QoL outcomes based 
on data collected from kidney transplant recipients that would the QoL experienced by 
that population of patients would provide an adjunct to the evaluation of the patient’s 
physical and disease specific outcomes in the clinical setting. 
 
 
Summary 
 
Improved graft survival and long-term patient survival following kidney 
transplantation has led to a growing interest in addressing the QoL of patients (De Geest 
& Moons, 2000). The wealth of data that is presently available regarding QoL and the 
instruments that have been developed to measure QoL have not been translated into the 
clinical setting for routine evaluation of QoL. Establishing benchmarks for the 
assessment of QoL is an initial step in translating years of research into practice.  
Standardized benchmark data would provide a baseline for interpreting individual patient 
QoL outcomes in such a way that the information could be used to educate patients prior 
to transplantation, allow transplant recipients to compare their QoL with others at similar 
points in time post transplantation, and identify patients who could benefit from 
interventions designed to improve QoL.  
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CHAPTER 3. METHODOLOGY 
  
 
Introduction 
 
This chapter will describe the methodology used to address the research question 
and study aim outlined in chapter one. It will include a discussion of the research design, 
the sample and sampling method, and analytical plan.  
 
 
Research Design 
 
This descriptive study is a secondary data analysis focused on the development of 
time-related centile ranges that document QoL outcome measure scores in four different 
time blocks following kidney transplantation. Time-related centile ranges such as these 
are used in clinical settings as benchmarks for patients and health care providers to 
compare the patient’s status or progress with others having similar characteristics. 
 
 
Research Question and Study Aim 
 
The primary outcome of this study was the creation of time-related centile 
reference ranges depicting QoL outcomes following kidney transplantation for use in 
patient evaluation and education. The research question (1) and study aim (2) were as 
follows: 
 
1. Do QoL outcomes differ within groups of patients categorized by gender and 
race? If so then: 
a) Do the QoL outcome measures for patients grouped by gender and 
race differ at four specific time intervals following transplantation? 
b) Which of the variables or combination of variables (gender and race) 
identify cohorts of patients most appropriate for creation of time-
related centile ranges used to illustrate QoL outcomes? 
 
2. Individual time-related centile ranges were established for scores on the SF-12 
and the Memphis Survey for each patient group identified in stage 1. The QoL 
measures included separate scores for the: 
a) SF-12: 
i. Physical Component Summary (PCS) 
ii. Mental Component Summary (MCS) 
b) Memphis Survey scores:  
i. Frequency score how often side effects occur) 
ii. Severity score (level of distress caused by the side effects)  
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Procedures 
 
The Patient Outcomes Registry for Transplant Effects of Life (PORTEL) Survey, 
a national data registry, was established in 2000 by Fujisawa Pharmaceuticals, and later 
supported by Astellas Pharmaceuticals, in response to increasing concern regarding the 
QoL of transplant recipients. The registry was designed to collect longitudinal data on 
QoL outcomes following solid organ transplantation. The PORTEL database houses data 
collected using a systematic approach to assessment of the QoL experienced by solid 
organ transplant recipients. The intent in the development of the registry was to provide a 
resource for data that could serve as a benchmark for evaluating the QoL of solid organ 
transplant recipients in order to develop strategies to improve QoL (Hathaway et al., 
2003b). With this goal in mind, the PORTEL survey design was based on a 
multidimensional QoL framework that encompassed both objective and subjective 
indicators of QoL. The PORTEL registry is unique in that it is a stand alone patient-
driven and patient-centered registry with data collected for the sole purpose of assessing 
QoL. It was not a part of a larger clinical study with additional goals that could influence 
the individual’s perception of their QoL.  
 
The participants in the registry represent transplant recipients recruited from 
multiple institutions and through multiple venues across the United States. Recruitment to 
the registry was both patient-centric and site-centric. The patient-centric recruitment was 
achieved through contact with transplant recipients at national transplantation meetings, 
community events, support groups, and direct mail. Site-centric recruitment occurred 
through four transplantation centers representing different regions of the United States, 
Unversity of Southern California, University of Alabama, Birmingham, University of 
Tennessee Health Science Center, and Unversity of Minnesota. Transplantation centers 
participating in data collection received IRB approval from their institution prior to 
enrollment of subjects (Hathaway, et al., 2003b).  The PORTEL database represents a 
more diverse sample of the population of transplant recipients than samples reported in 
which data are collected from a single institution.  
 
Participants were entered into the registry and data were collected from 2000-
2005. PORTEL registry participants completed surveys at 6 month intervals during the 
data collection period. Enrollment and participation in the registry was open to any solid 
organ transplant recipient who had a functioning graft and was greater than 16 years of 
age at the time that the survey was completed.  All participants enrolled in the registry 
were solid organ transplant recipients including, heart, lung, kidney, kidney-pancreas, 
and liver transplant recipients. Participants received an incentive in the form of a $10 
dollar Target gift certificate each time a survey was completed. Year to year retention in 
the database was approximately 70 percent.  
 
The design of the PORTEL Registry survey instrument was based on the four 
cornered QoL framework discussed in chapter one. The instrument was comprised of 100 
items organized to capture demographic variables, clinical outcomes, medications, and 
side effects (Hathaway, Winsett, Prendergast, & Subaiya, 2003). The content of the 
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survey addressed each of the five domains described in the QoL framework for the 
registry: QoL, health factors, social factors, major health factors, and major life events.  
 
 
Quality of Life Instruments Included in the PORTEL Registry Survey 
 
 
12-Item Short-Form Health Survey 
 
The SF-12 is an instrument that has been used to document QoL in the general 
population as well as groups of patients with various chronic illnesses. It is comprised of 
a subset of 12 items from the SF-36 and was developed to provide an alternative to the 
longer form, be easier to administer and yet provide the same reliability as the longer SF-
36 (Ware, Kosinski, & Keller, 1996).  The SF-36 has been widely used to evaluate health 
related quality of life in transplant recipients and is considered the gold standard for 
measuring QoL (Aasebo, Midtvedt, Hartmann, & Stavem, 2005; Fiebiger, Mitterbauer, & 
Oberbauer, 2004; Griva et al., 2002; Pinson et al., 2000; Rebollo et al., 2000). The SF-12 
has been shown to correlate with the SF-36 in assessing QoL trauma patients, individuals 
with cervical spondylosis, and persons infected with HIV (Delate & Coons, 2000; Kiely, 
Brasel, Guse, & Weigelt, 2006; Singh, Gnanalingham, Casey, & Crockard, 2006).  
 
The SF-12 is composed of two domains comprising a Mental (MCS) and Physical 
Component Summary (PCS). Mental and physical factors were found to account for 80 to 
85 percent of the variance in the SF-36 (Ware et al., 1996). Psychometric methods were 
used to reduce the number of health dimensions in the SF-36 to those included in the SF-
12 and maintain comparable information (Ware et al., 1996). The SF-12 is scored from 0-
100 with higher scores indicating better QoL. 
  
 
Memphis Survey 
 
A disease specific instrument, the Memphis Survey was included in the PORTEL 
instrument to document side effects of immunosuppressant medications. The survey was 
developed in 1997 by a group of researchers at University of Tennessee Health Science 
Center. The development of the Memphis Survey was unrelated to the establishment of 
the PORTEL registry (Hathaway et al., 2003b). The survey was designed to evaluate the 
frequency and severity of side-effects of immunosuppressive regimens on QoL in solid 
organ transplant recipients (Hathaway et al., 2003b). A multi-stage factor analysis was 
used to identify side effects experienced by patients taking a variety of 
immunosuppressant agents (Winsett et al., 2004). The subscales of the Memphis survey 
are emotional burden, life/role responsibilities, mobility, gastrointestinal distress, and 
miscellaneous side-effects which include items related to enlarged gums, increased 
hunger, sleeping, weight gain, increased hair growth, infections, trembling hands, high 
blood pressure, easy bruising, loss of interest in sex, and sexual performance (Winsett et 
al., 2004). Symptoms were assessed for occurrence and the level of distress incurred by 
the patient. Symptoms were coded on a 0-4 scale, zero being not at all and 4 being 
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always. Cumulative subscale scores for frequency of occurrence and severity of the 
symptom were reported for each patient ranging from 0-160. The higher number 
indicating a worse side-effect profile (Hathaway et al., 2003b). Reliability and validity of 
the Memphis Survey was demonstrated by Winsett, et al. (2004) in a national survey of 
505 transplant recipients designed to quantify the consequences of the side effects of 
immunosuppressant therapy on QoL. 
 
 
Data Extraction 
 
Data for this study were extracted from the PORTEL Registry database. Inclusion 
criteria for the study were recipients of a single kidney transplantation who were between 
the ages of 18 and 65 at the time the survey was completed and greater than 14 days from 
the transplant surgery. The total PORTEL database includes 7,327 surveys completed by 
1,434 recipients of solid organ transplantation. The initial data extraction identified 3,144 
surveys completed by 681 individuals who had undergone single kidney transplantation. 
Time intervals were established for construction of time-related centile ranges 
representing four separate time brackets between the transplant surgery and survey 
completion: less than 4 months from transplantation, 4 months to 18 months, 19 months 
to 36 months, and greater that 36 months from transplantation. These specific time 
brackets were selected to allow for even distribution of the surveys and to be consistent 
with times typically used for clinical assessment of patients and in post-transplantation 
follow-up studies. Because individuals contributed multiple surveys to the database, care 
was taken to assure that only one survey from each individual transplant recipient was 
included in each time bracket. The first survey completed by an individual within each 
time bracket was selected for inclusion. If a patient contributed additional surveys, the 
others were excluded. This process eliminated 1,894 surveys leaving 969 for study 
inclusion in the study.  
 
Only Caucasian and African American participants were selected for inclusion in 
the study because the number of participants of other ethnic or racial association was 
inadequate for data analysis. Of the 969 surveys selected, 22 surveys were eliminated 
because they did not include QoL data and 4 surveys were eliminated because they did 
not include information about gender. The final sample consisted of 943 surveys 
completed by 515 recipients of a single kidney transplantation. 
 
Demographic data, clinical information and QoL outcomes were extracted from 
each survey to describe the sample and address the research question and study aim. 
Demographic data included age, income, education, working status, social support, living 
arrangements, immunosuppressant regimens, and insurance coverage. Clinical 
information included comorbidities, number of infection and rejection episodes, 
frequency of hospitalization and number of hospital days since transplantation. Data 
extracted to address the research questions included race, gender, the Memphis Survey 
Frequency and Severity scores and the SF-12 PCS and MCS scores.  
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Sample 
 
The 943 PORTEL Registry Surveys included in this study were completed by 515 
individuals, 246 contributed a survey in only one time bracket, 128 individuals 
contributed a survey in each of two time brackets, 123 contributed a survey in three time 
brackets, and 18 transplant recipients contributed a survey in all 4 time brackets. No 
PORTEL Registry participant was represented in any time bracket more than once. The 
description of the sample is reported by time intervals since transplantation in order to 
provide a description of the portion of the sample included in each time bracket.  
 
 
Description of the Sample 
 
The 943 surveys were completed by 484 (51.3%) men and 459 (48.7%) women.  
Seven hundred fifty one (79.6%) were completed by Caucasians and 192 (20.4%) by 
African Americans. The average age at the time of survey completion was 46 years with 
a standard deviation of 11.3 years.  
 
The gender and race distribution of the individual transplant recipients included in 
this study was compared to the data from the United Network for Organ Sharing (UNOS) 
data. UNOS administers the Organ Procurement and Transplantation Network (OPTN) 
and is responsible for collecting and managing data about all transplantation events that 
occur in the United States. The distribution of racial and gender groups in the PORTEL 
sample differs from that of the UNOS data (χ2 = 25.03, α=0.01).  A comparison of the 
gender and racial distribution of this sample with the UNOS data is presented in Table 
3.1. The percentage of Caucasian males and African-American females in the sample 
from the PORTEL registry were consistent with the population reported by UNOS. 
However, African American males comprised only 9.5% of the study sample compared 
with 16.24% reported by UNOS. The percentage of Caucasian females in the study 
sample was higher than that reported in the UNOS database, 35.7% and 28.52% 
respectively.  
 
 
Health Status 
 
Health status includes both the health factors and major health events that 
transplant recipients deal with on a daily basis and episodically which impact QoL 
(Hathaway et al., 2003b). Comorbidities, rejection episodes, hospital admissions, hospital 
days and infections that were reported on each survey were included in the study.  The 
PORTEL Survey is a self-report questionnaire; as a result all surveys were not complete. 
 
 
Comorbidities. Increased long term survival of transplant recipients leads to 
increased prevalence of secondary complications of transplantation, including 
osteoporosis (Cohen & Shane, 2003; Crippin, 2001), diabetes, and hyperlipidemia 
Table 3.1.  Comparison of Sample Demographic Distribution with UNOS Data. 
 
 
Demographic Group 
 
PORTEL Sample UNOS 
 
Caucasian Male 42.3% 44.16% 
 
Caucasian Female 35.7% 28.52% 
 
African American Male 9.5% 16.24% 
 
African American Female 
 
12.4% 11.10% 
*Based on OPTN data as of May 8, 2008. 
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(Reuben, 2001). Comorbidities, either pre-existing or those that develop following 
transplantation have an impact on the well-being and QoL of transplant recipients. The 
survey asked participants if they had been treated for diabetes, hypertension, 
hypercholesterolemia, or osteoporosis since transplantation. Treatment for comorbidities 
was reported on 761 surveys.Interestingly, 200 surveys reported no comorbidities. 
Multiple comorbidities were reported on 328 surveys, 200 reported two, 106 
reportedthree and 22 reported treatment for four comorbidities. Table 3.2 reports the 
percent of surveys reporting treatment for hypertension, cholesterol, diabetes, or 
osteoporosis ineach time bracket. The incidence of diabetes and hypertension are 
relatively stable across time. 
 
The frequency of treatment for osteoporosis and hypercholesterolemia is lower for 
individuals in the early months post transplantation and was increased at the points 
farthest removed from the transplantation. At less than 4 months post transplantation, 
4.7% of surveys reported treatment for osteoporosis and 25.7% reported treatment for 
hypercholesterolemia. At greater than 36 months post transplantation, 23% of surveys 
reported treatment for osteoporosis and 46.7% reported treatment for 
hypercholesterolemia. 
 
 
Rejection, Infection, Hospital Admissions, and Hospital Days. The incidence of 
rejection episodes in the sample is low with the majority of surveys reporting no rejection 
episodes. The peak period for rejection was in the 4-18 month post transplant block with 
10.3% of surveys reporting 1 to 2 rejection episodes representing 26 surveys. Table 3.3 
lists the incidence of rejection episodes in each time bracket.  
 
Frequency of infection was reported as the number of infections treated since 
transplantation. No information was available regarding severity of infection. Most 
surveys reported that no treatment for infection had been required since transplantation. 
Of those reporting that they had been treated for an infection, the most common number 
of infections reported was 1 to 2. Over time, the number of infections was relatively 
stable. The actual number of infections reported in each time bracket is reported in Table 
3.4. 
 
The number of hospital admissions and the number of days spent in the hospital is 
reported in Tables 3.5 and 3.6. The reported frequency of hospital admissions or hospital 
days in each time bracket represents the cumulative number of hospitalizations or 
hospital days since transplantation, not the number occurring during the designated time 
bracket. The majority of surveys reported no hospitalizations since transplantation. A  
greater percentage of surveys reported no hospital days at greater than 36 months post 
transplantation (53.3%)  than at less than 4 months post transplantation (29.2%). Few 
surveys reported 5 or more hospitalizations in any time bracket and few surveys reported 
more than 21 days in hospital. More hospital days were reported during the less than 4 
month post transplantation period than the later time blocks, which would be consistent 
with surgical recovery. The percentage of survey that did not report health status  
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Table 3.2.  Comorbidity by Time Bracket Since Transplantation. 
 
  
Time Since Transplantation 
 
 
Cormorbidity 
 
<4 months 
n=213 
4-18 months 
n=213 
19-36 months 
n=199 
>36 months 
n=134 
 
Diabetes 
 
50 
23.4% 
43 
20.2% 
47 
23.6% 
37 
27.4% 
 
Hypertension 
 
 
118 
55.1% 
106 
49.8% 
113 
56.8% 
80 
59.3% 
 
Osteoporosis 
 
10 
4.7% 
30 
14.1% 
48 
24.1% 
31 
23.0% 
 
Increased 
Cholesterol 
 
55 
25.7% 
76 
35.7% 
94 
47.2% 
 
63 
46.7% 
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Table 3.3.  Frequency of Rejection Episodes by Time Since Transplantation. 
 
  
Time Since Transplantation 
 
 
Rejection 
Episodes 
<4 months 
n=236 
4-18 months 
n=253 
19-36 months 
n=225 
>36 months 
n=229 
 
0 
 
200 
84.7% 
208 
82.2% 
203 
90.2% 
181 
79% 
 
1-2 
 
15 
6.4% 
26 
10.3% 
12 
5.3% 
7 
3.1% 
 
3-4 
 
5 
2.1% 
2 
.8% 
1 
.5% 
3 
1.3% 
 
5 or more 
 
4 
1.7% 
0 
.0% 
0 
.0% 
1 
.4% 
 
Unknown 
 
12 
5.1% 
17 
6.7% 
9 
4% 
37 
16.2% 
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Table 3.4.  Number of Reported Infections by Time Since Transplantation. 
 
  
Time Since Transplantation 
 
 
Infections 
 
<4 months 
n=236 
4-18 months 
n=253 
19-36 months 
n=225 
>36 months 
n=229 
0 
 
152 
64.4% 
 
153 
60.5% 
 
152 
67.6% 
 
138 
60.3% 
1-2 
 
61 
25.8% 
 
67 
26.5% 
 
55 
24.4% 
 
42 
18.3% 
3-4 
 
4 
1.7% 
 
13 
5.1% 
 
8 
3.6% 
 
13 
5.7% 
5 or more 
 
1 
0.4% 
 
0 
.0% 
 
2 
0.9% 
 
3 
1.3% 
Unknown 
 
 
18 
7.9% 
 
 
20 
7.9% 
 
 
8 
3.6% 
 
33 
14.4% 
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Table 3.5.  Frequency of Hospital Admissions by Time Since Transplantation. 
 
  
Time Since Transplantation 
 
 
Hospital 
Admissions 
<4 months 
n=236 
4-18 months 
n=253 
19-36 months 
n=225 
>36 months 
n=229 
 
0 
 
162 
68.6% 
163 
64.4% 
180 
80% 
153 
66.8% 
 
1-2 
 
57 
24.2% 
61 
24.1% 
31 
13.8% 
20 
8.7% 
 
3-4 
 
5 
2.1% 
7 
2.8% 
2 
.9% 
7 
3.1% 
 
5 or more 
 
1 
0.4% 
3 
1.3% 
1 
0.4% 
1 
0.4% 
 
Unknown 
 
11 
4.7% 
19 
7.5% 
11 
4.9% 
48 
21% 
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Table 3.6.  Number of Hospital Days by Time Since Transplantation. 
 
  
Time Since Transplantation 
 
 
Hospital Days 
 
<4 months 
n=236 
4-18 months 
n=253 
19-36 months 
n=225 
>36 months 
n=229 
 
0 
 
69 
29.2% 
127 
50.2% 
134 
59.6% 
122 
53.3% 
 
1-10 
 
116 
49.2% 
84 
33.2% 
70 
31.1% 
52 
22.7% 
 
11-20 
 
22 
9.3% 
12 
4.7% 
5 
2.2% 
4 
1.7% 
 
21-30 
 
11 
4.7% 
6 
2.4% 
3 
1.3% 
1 
0.4% 
 
>31 
 
7 
3.0% 
4 
1.6% 
1 
0.4% 
2 
0.9% 
 
Unknown 
 
11 
4.7% 
20 
7.9% 
12 
5.3% 
48 
21% 
 
 
indicators was higher in the greater than 36 months post transplantation group than in any 
other group (21%). 
 
 
Immunosuppressant Regimen. The current immunosuppressant regimen was 
reported on 760 surveys. The drugs included in the immunosuppressant regimens 
indicated on the surveys are reported in Table 3.7.  Prednisone, the calcineurin inhibitors, 
cyclosporine and tacrolimus, and mycophenolate mofetil (Cellcept), an antiproliferative 
agent, were the most common agents indicated. The majority of surveys (62%) reported a 
3 drug regimen. 
 
 
Social Factors 
 
Social factors, including the individual’s marital status, social support, and 
working status have been reported to correlate with better QoL in a number of studies 
(Blake, Codd, Cassidy, & O'Meara, 2000; Yildirim, 2006). The QoL framework that 
forms the basis for both the PORTEL registry and this study included social support, 
health care coverage and financial resources. 
 
 
Social Support. Social support data collected through the PORTEL survey 
included the individual’s living situation and the assistance that was available to them. 
Most surveys reported that the transplant recipient lived with their spouse or a significant 
other, with percentages ranging from 64.4% to 71.1%. More people reported living alone 
at greater than 36 months following transplantation (18.3%) than in the earlier time 
brackets (Table 3.8).  
 
Social support in the form of available assistance ranged from “no available 
assistance” to “more people available to help than I can count”. Very few surveys 
reported that the individual had no available assistance. Most survey reported that they 
had people available to assist them when needed (Table 3.9). Assistance was not defined. 
 
 
Health Care Coverage. Health care coverage was reported by the majority of 
participants. Medicare was most frequently reported with 621 surveys indicating 
Medicare coverage. Medicaid enrollment was reported on only 92 surveys. Private 
insurance was reported by 578 individuals. Both private and public health care coverage 
was reported by 321 individuals. Table 3.10 reports health care coverage by time bracket 
since transplantation. 
 
 
Employment, Income, Education. Employment has been shown to correlate with 
better QoL (Neipp et al., 2006). The working status of the individual was reported on 
only 440 of the 943 surveys. Of that number, 203 (46.1%) across all time brackets 
reported that they were working full-time or part time. Examination of all time brackets 
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Table 3.7.  Immunosuppressant Agent by Time Since Transplantation. 
 
  
Time Since Transplantation 
 
 
Immunosuppressant 
Agent 
<4 months 
n=214 
4-18 months 
n=213 
19-36 months 
n=199 
>36 months 
n=136 
 
Prednisone 
 
155 
72.4% 
151 
70.9% 
139 
69.8% 
115 
85.2% 
 
Imuran 
 
2 
.9% 
4 
1.9% 
4 
2.0% 
14 
10.4% 
 
Calcineurin 
Inhibitors: 
    
 
Prograf 
 
110 
51.4% 
109 
51.2% 
101 
50.8% 
59 
43.7% 
 
Neoral 
 
71 
33.2% 
79 
37.1% 
55 
27.6% 
45 
33.6% 
 
Generic 
Cyclosporine 
 
6 
2.8% 
11 
5.2% 
20 
10.1% 
17 
12.7% 
 
Mycophenolate 
Mofetil (Cellcept) 
 
159 
74.3% 
162 
76.1% 
135 
67.8% 
83 
61.9% 
 
Rapamune 
 
28 
13.1% 
34 
16.0% 
35 
17.6% 
12 
9.0% 
 
Other 
 
16 
7.5% 
13 
6.1% 
13 
6.5% 
8 
6.0% 
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Table 3.8.  Living Situation by Time Bracket Since Transplantation. 
 
  
Time Since Transplantation 
 
 
Living Situation 
 
<4 months 
n=236 
4-18 months 
n=253 
19-36 months 
n=225 
>36 months 
n=229 
 
Living with spouse 
or significant other 
 
152 
64.4% 
175 
69.2% 
160 
71.1% 
149 
65.1% 
 
Single, living with 
family or friends 
 
51 
21.6% 
39 
15.4% 
31 
13.8% 
31 
13.5% 
 
Single, living alone 
 
 
26 
11% 
 
31 
12.3% 
 
27 
12% 
 
42 
18.3% 
 
Widowed 
 
 
4 
1.7% 
 
4 
1.6% 
 
5 
2.2% 
 
3 
1.3% 
 
Unknown 
 
3 
1.3% 
4 
1.6% 
2 
.9% 
4 
1.8% 
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Table 3.9.  Available Assistance by Time Since Transplantation. 
 
 
 
Time Since Transplantation 
 
 
Available 
Assistance 
<4 months 
n=236 
4-18 months 
n=253 
19-36 months 
n=225 
>36 months 
n=229 
 
More people 
available than I 
can count 
32 
13.6% 
44 
17.4% 
49 
21.8% 
27 
11.9% 
 
Several friends and 
family available 
116 
49.2% 
92 
36.4% 
59 
26.2% 
85 
37.4% 
 
Just a few friends 
and family 
78 
33.1% 
105 
41.5% 
100 
44.4% 
95 
41.5% 
 
No available to 
help 
5 
2.1% 
6 
2.4% 
8 
3.6% 
15 
6.6% 
 
Unknown 
 
5 
2.1% 
6 
2.4% 
9 
4.0% 
7 
3.1% 
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Table 3.10.  Health Care Coverage by Time Since Transplantation. 
 
 
 
 
Time Since Transplantation 
 
 
Health Care 
Coverage 
<4 months 
n=236 
4-18 months 
n=253 
19-36 months 
n=225 
>36 months 
n=229 
 
Medicare 
 
170 
72% 
185 
73.1% 
165 
73.3% 
101 
44.1% 
 
Medicaid 
 
50 
21.2% 
15 
6% 
15 
7% 
12 
5% 
 
Private Insurance 
 
134 
56.8% 
147 
58.1% 
148 
65.8% 
149 
65.1% 
 
 
 
  
revealed that 153 (34.7%) surveys reported that the respondent was not working; 139 
(31.6%) due to their disease and 14 (3%) by choice.  The number employed in each time 
brackets is reported in Table 3.11. 
 
The annual income and education level of the participants in the sample is 
reported in Tables 3.12 and 3.13. Reported income ranged from less than $10,000 to 
greater than $151,000. The source of income was not indicated. Education ranged from 
less than eighth grade to post graduate or professional school. The most frequent response 
in all time brackets was some college or technical school.  
 
 
Analytical Plan 
 
The study progressed in two phases guided by the research question and study 
aim. Phase 1 addressed the research question and identified how the study sample 
differed on QoL outcomes based on gender and race, at four separate time brackets post-
transplantation. Phase 2 of the study focused on the study aim which involved generating 
time-related centile ranges to be used in clinical practice to monitor and evaluate kidney 
transplant recipients. 
 
 
Research Question 
 
The QoL outcome measures for each racial and gender specific demographic 
group were compared at each time following transplantation in order to determine if the 
scores on each QoL outcome by racial and gender specific demographic group were 
homogenous enough to include all groups in a single centile range. Descriptive statistics 
for the QoL outcomes SF-12, MCS and PCS scores, and Memphis Survey Frequency and 
Severity scores of each group were completed including the mean, median, range, 
standard deviation and tests for normality at each time point post transplantation. The 
QoL outcome scores for each group at each time bracket were not normally distributed. 
In addition, the number of scores in the African American population was fewer than that 
required for the Central Limit Theorem to apply (n=30) for the use of parametric 
statistics. Therefore, a nonparametric statistical procedure, the Kruskal-Wallis test was 
used to evaluate differences between gender and racial groups for the QoL outcome 
scores at each time bracket post transplantation.  
 
 
Study Aim: Construction of Centile Ranges 
 
Time-related centile ranges were constructed by using SPSS 15 to identify the 
5th, 25th, 50th, 75th, and 95th percentiles for each QoL outcome at each time point. 
These percentiles were plotted for each QoL outcome at each time bracket following 
transplantation.
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Table 3.11.  Employment Status by Time Since Transplantation. 
 
 
 
Time Since Transplantation 
 
 
Employment 
Status 
<4 months 
n=142* 
4-18 months 
n=125 
19-36 months 
n=94 
>36 months 
n=79 
 
Working full time 
 
30 
21.1% 
47 
37.6% 
47 
50% 
38 
48.1% 
 
Working part time 
by choice 
 
5 
3.5% 
10 
8% 
3 
3.2% 
3 
3.8% 
 
Working part time 
due to disease 
 
8 
5.6% 
7 
5.6% 
1 
1.1% 
4 
5.1% 
 
Not working by 
choice 
 
3 
2.1% 
3 
2.4% 
4 
4.3% 
4 
5.1% 
 
Not working due 
to disease 
 
68 
47.9% 
31 
24.8% 
21 
22.3% 
19 
24.1% 
 
Not working, 
unable to find 
employment 
 
5 
3.5% 
7 
5.6% 
5 
5.3% 
5 
6.3% 
 
Retired 
 
23 
16.2% 
20 
16% 
13 
13.8% 
6 
7.6% 
* n = number reporting employment status 
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Table 3.12.  Annual Income by Time Since Transplantation. 
 
 
 
Time Since Transplantation 
 
 
Annual Income 
 
<4 months 
n=236 
4-18 months 
n=253 
19-36 months 
n=225 
> 36 months 
n=229 
 
<$10,000 
 
37 
16.7% 
27 
11.5% 
21 
10.4% 
23 
10.6% 
 
$11,000-$25,000 
 
37 
16.7% 
47 
20.1% 
34 
16.8% 
30 
13.8% 
 
$26,000-$50,000 
 
49 
22.1% 
67 
28.6% 
61 
30.2% 
64 
29.8% 
 
$51,000-$75,000 
 
34 
15.3% 
35 
15.0% 
39 
19.3% 
41 
19.1% 
 
$76,000-$150,000 
 
29 
13.1% 
25 
10.7% 
17 
8.4% 
19 
8.8% 
 
>$151,000 
 
5 
2.3% 
10 
4.3% 
9 
4.5% 
10 
4.7% 
 
Unknown 
 
45 
19.2% 
42 
16.6% 
44 
19.6% 
42 
18.3% 
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Table 3.13.  Education by Time Since Transplantation. 
 
 
 
Time Since Transplantation 
 
 
Education 
 
<4 months 
n=236 
4 - 18 months 
n=253 
19 - 36 months 
n=225 
> 36 months 
n=229 
 
8th grade or less 
 
5 
2.1% 
2 
.8% 
1 
.4% 
4 
1.8% 
 
9th-12th grade 
 
17 
7.2% 
9 
3.6% 
8 
3.6% 
6 
2.6% 
 
High School 
 
57 
24.2% 
63 
24.9% 
49 
21.8% 
40 
17.5% 
 
Some college or 
technical school 
 
90 
38.1% 
101 
39.9% 
91 
40.4% 
92 
40.5% 
 
4-year 
Baccalaureate 
College 
 
43 
18.2% 
51 
20.2% 
45 
20.0% 
52 
22.9% 
 
Graduate School 
 
11 
4.7% 
14 
5.5% 
18 
8.0% 
20 
8.8% 
 
Postgraduate/ 
Professional 
School 
 
9 
3.8% 
11 
4.3% 
10 
4.4% 
14 
6.2% 
 
Unknown 
 
4 
1.7% 
2 
.8% 
3 
1.3% 
1 
.4% 
CHAPTER 4. RESULTS 
 
 
The results and discussion section of this dissertation have been written in 
manuscript format. As a result supporting material, including descriptive statistics for 
the Memphis Survey Subscale Scores, the Memphis Survey Total Scores, and the SF-12 
scores which are of interest for the purposes of the dissertation but not necessarily for a 
manuscript have been placed in Appendices A and B. Background material presented in 
other chapters has been included in this section to provide the information necessary for 
a manuscript. 
  
 
Introduction 
 
Quality of life (QoL) is commonly viewed as an important indicator of successful 
chronic illness management (Leplege & Hunt, 1997), particularly for conditions such as 
renal failure in which transplantation is the preferred therapy primarily because of the 
associated improvement in QoL (Feibiger, Mitterbauer, & Oberbauer, 2004). Despite 
extensive research, routine assessment of QoL has not been widely translated into clinical 
practice as a means to augment clinical decision making, identify patients who would 
benefit from interventions, or to educate patients about anticipated QoL outcomes 
(Higginson & Carr, 2001).  Kidney transplantation is no exception. 
 
Time-related centile ranges have been developed for many clinical outcomes such 
as growth and bone density, and provide reference ranges that are used to interpret a 
patient’s health status as compared to a normative population, or to monitor disease. 
Similar reference ranges for QoL outcome data would provide a context for interpreting 
QoL data for patients and providers in the transplantation setting. The purpose of this 
study was therefore to create time-related centile ranges from data collected in a national 
data registry that depict QoL outcomes in such a way that they that could be used as 
benchmarks in evaluating the QoL of patients following kidney transplantation in the 
clinical setting. 
  
 
Background and Significance 
 
QoL has been described as the difference between the patient’s expectation of a 
situation and their actual experience (Carr, Gibson, & Robinson, 2001). The patient’s 
assessment of their QoL following kidney transplantation may be shaped by their pre-
transplantation expectations of what life after transplantation would be like. Patients 
contemplating transplantation or being followed post transplantation often seek 
information related to QoL expectations following transplantation and how their QoL 
compares with other transplant recipients. Benchmarks that reflect QoL following kidney 
transplantation would provide an additional tool in the clinical armamentarium to 
augment post transplantation care by providing a context for interpreting QoL measures.  
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There are relatively few examples in which QoL measurement has been used to 
guide clinical decision making for individual patients (Levine & Ganz, 2002). While 
there  is general agreement that discussion of QoL is beneficial, few studies have 
demonstrated that measuring QoL outcomes actually changes clinical decision making or 
patient outcomes (Espallargues, Valderas, & Alonso, 2000; Greenhalgh, Long, & Flynn, 
2005).  However, even in studies that do not demonstrate changes in clinical or QoL 
outcomes, measuring QoL in routine practice has been demonstrated to increase 
communication between patients and providers about QoL indicators (Detmar, Muller, 
Schornagel, Wever, & Aaronson, 2002). Measuring QoL in oncology practice, and 
providing feedback to patients, has led to increased discussion of nonspecific symptoms 
and better QoL and emotional functioning without prolonging the duration of patient 
encounters (Velikova et al., 2004). Although most studies using QoL instruments did not 
demonstrate changes in clinical decision making or QoL outcomes, the process of 
increasing communication seems to have benefit in patient care. Higginson & Carr 
(2001) cite several potential uses for QoL measures in the clinical setting directly related 
to clinical care including prioritizing problems, facilitating communication, screening for 
potential problems, identifying preferences of patients and monitoring changes or 
responses to treatments. While QoL measures do not substitute for physiologic evaluation 
of disease, they capture the personal and social context of the patient for a more holistic 
approach to patient assessment.  
 
 
Time-Related Centile Ranges 
 
Reference ranges, often referred to as normal ranges, have long been used in health 
care to evaluate the health status of individual patients on some specific parameter by 
comparing them to an standard established from a “normal” population (Wright & 
Royston, 1997). The range of normal for a given variable is typically defined as the range 
of values for that variable that fall between the 2.5th and the 97.5th percentile in the 
population of interest (Griffiths, Iles, Koduah, & Nix, 2004).  The assumption is made 
that the reference population in which the variable is measured is a healthy population 
representative of “normal” or “healthy” individuals, thus the term normal range. The 
variables that are reported in a reference range are often affected by other characteristics 
of the representative population (Wright & Royston, 1997). When the variable in 
question is strongly dependent on a covariate such as time, a simple reference range is 
inadequate for evaluation (Cole & Green, 1992).  A common example of a reference 
range established to follow change in a variable over time is the series of ranges that have 
been established to monitor growth rates in childhood. Growth charts are routinely used 
by health care providers to evaluate the growth of children over time, to identify those 
children who are not growing at the anticipated rate, or whose height or weight is outside 
of the desired range. The time-related centile ranges for QoL outcomes of kidney 
transplant recipients proposed in this study could be used in a similar manner to follow 
QoL outcomes over time as well as a evaluating QoL at a particular point in time. 
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Methods 
 
 
PORTEL Registry 
 
Data for the creation of time-related centile ranges in this study was extracted 
from the Patient Outcomes Registry for Transplant Effects on Life (PORTEL), a national 
data registry, established in 2000 by Fujisawa Pharmaceuticals, and later supported by 
Astellas Pharmaceuticals, in response to increasing concern regarding the QoL of 
transplant recipients. The registry was designed to collect longitudinal data on QoL 
outcomes following solid organ transplantation and incorporated a systematic approach to 
the assessment of QoL experienced by solid organ transplant recipients. The intent of the 
registry was to provide a resource for QoL data that could serve as a benchmark for 
assessing QoL in solid organ transplantation leading to the development of strategies to 
improve QoL (Hathaway et al., 2003b). With this goal, the PORTEL survey design was 
based on a multidimensional QoL framework that included five interrelated domains; 
health and social factors, major life and health events and QoL. Health factors are those 
issues that individuals deal with on a daily basis that influence QoL such as the effects of 
immunosuppressant drugs and co-morbidities that require daily attention and therefore 
influence QoL. Social factors include situations and events that define an individual’s 
social environment and include the financial resources available to the individual, health 
care coverage, and the social support that the transplant recipient has (Hathaway et al., 
2003b). Major life and health events are more episodic in nature but may be more 
disruptive to the established routine of the individual or the family (Hathaway et al, 
2003b). Major health events include rejection episodes, hospitalizations, or a new 
diagnosis. A major life event as defined in the PORTEL framework may be a divorce, 
death in the family, or loss of a job. Health and social factors and major life and health 
events influence, and are influenced by, the QoL that an individual is experiencing. The 
PORTEL survey instrument was a 100 item survey developed to assess the five domains 
included in the PORTEL framework.  
 
The PORTEL registry was a stand alone patient-driven and patient-centered 
registry with data collected for the sole purpose of assessing QoL. The participants in the 
registry represent transplant recipients recruited from multiple institutions and through 
multiple venues across the United States. Recruitment to the registry was both patient-
centric and site-centric. Patient-centric recruitment was achieved through contact with 
transplant recipients at national transplantation meetings, community events, support 
groups, and direct mail. Site-centric recruitment was accomplished through four 
transplantation centers representing different regions of the United States; Unversity of 
Southern California, University of Alabama, Birmingham, University of Tennessee 
Health Science Center, and University of Minnesota. Transplantation centers 
participating in data collection received IRB approval from their institution prior to 
enrollment of subjects (Hathaway, Winsett, Prendergast, & Subaiya, 2003).  The 
PORTEL database represented a more diverse sample of the population of transplant 
recipients than a sample drawn from a single institution and, as such, was appropriate for 
creation of time-related centile ranges for use in a variety of settings. 
 41 
 
It has been recommended that evaluation of QoL should include a generic QoL 
instrument and a disease specific instrument (Hathaway, Winsett, et al., 2003). The 12-
Item Short Form-Health Survey (SF-12) was chosen by the designers of the PORTEL 
survey as the generic instrument and the Memphis Survey as the disease specific 
instrument. The SF-12 has been used to document QoL in the general population as well 
as in the evaluation of QoL of patients with a variety of chronic conditions. Comprised of 
a subset of 12 items derived from the 36-Item Short-Form Health Survey (SF-36), the 
gold standard for assessment of QoL, the SF-12 was developed to provide an alternative  
instrument that would be shorter, easier to administer and yet provide the same reliability 
as the longer SF-36 (Ware, Kosinski, & Keller, 1996).  The SF-12 has been correlated 
with the SF-36 in assessing QoL of trauma patients, individuals with cervical 
spondylosis, and persons infected with HIV (Delate & Coons, 2000; Kiely, Brasel, Guse, 
& Weigelt, 2006; Singh, Gnanalingham, Casey, & Crockard, 2006). The SF-12 is 
composed of two domains, the Mental Component Summary and Physical Component 
Summary.  Each Summary is scored on a 0-100 scale with higher scores indicating better 
QoL. 
 
The Memphis Survey was included in the PORTEL survey to document side 
effects of immunosuppressant medications. The survey was developed in 1997 by a 
group of researchers at University of Tennessee Health Science Center. The instrument 
was designed to evaluate the frequency and severity of side-effects of 
immunosuppressant regimens on QoL in transplant recipients (Hathaway, Winsett, et al., 
2003). A multi-stage factor analysis was utilized to identify those side effects 
experienced by patients on a variety of immunosuppressant regimens (Winsett et al., 
2004). The subscales included in the Memphis survey are emotional burden, life/role 
responsibilities, mobility, gastrointestinal distress, and miscellaneous side-effects which 
include items related to enlarged gums, increased hunger, sleeping, weight gain, 
increased hair growth, infections, trembling hands, high blood pressure, easy bruising, 
loss of interest in sex, and sexual performance (Hathaway, Winsett, et al., 2003). 
Symptoms are assessed for frequency of occurrence and the severity of the side effect and 
coded on a 0-4 scale. Total scores are tabulated from the subscale scores for frequency of 
occurrence and for severity of the symptom to provide an overall estimate of the side 
effect profile and degree of distress. Memphis Survey total scores range from 0-160, the 
higher number indicating a worse side-effect profile (Hathaway, Winsett, et al., 2003). 
Reliability and validity of the Memphis Survey has been demonstrated by Winsett, et al. 
(2004) in a national survey of 505 kidney transplant recipients. 
 
 
Data Extraction 
 
Data for this study were extracted from the PORTEL Registry database. The total 
PORTEL database includes 7,327 surveys completed by 1,434 recipients of any solid 
organ transplantation. Inclusion criteria for the current study were Caucasian and African 
American PORTEL registry participants between the ages of 18 and 65 who had 
undergone one kidney transplantation and were greater than 14 days from transplant 
surgery when the survey was completed. Initial data extraction identified 3,144 surveys 
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completed by 681 individuals who had undergone a single kidney transplantation. 
PORTEL data were collected longitudinally over a five year period, as a result, individual 
transplant recipients contributed multiple surveys to the registry.  
 
Four separate time brackets between the transplantation surgery and completion 
of the survey were established for construction of time-related centile ranges: less than 4 
months from transplantation, 4 months to 18 months, 19 months to 36 months, and 
greater that 36 months from transplantation. The identified time brackets allowed for 
even distribution of the surveys and were consistent with times typically used for clinical 
follow-up and in post-transplantation studies. Only one survey from each individual was 
included in each time block for which time-related centile ranges were established. The 
first survey completed by an individual within each time bracket was selected for 
inclusion leaving 943 surveys completed by 515 recipients; 246 individuals were 
represented in only one time bracket, 128 individuals contributed a survey to two time 
brackets, 123 contributed a survey to three time brackets, and 18 transplant recipients 
contributed a survey to all 4 time brackets.  
 
 
Sample 
 
Of the 943 surveys included in the study, 484 (51.3%) were men and 459 were 
(48.7%) women.  Seven hundred fifty one (79.6%) surveys were completed by 
Caucasians and 192 (20.4%) by African Americans. The average age at survey 
completion was 46 years with a standard deviation of 11.3 years. The gender and racial 
distribution of the sample in this study was compared to the data from the United 
Network for Organ Sharing (UNOS) data and is reported in Table 3.1.  
 
 
Data Analysis 
 
The Qol outcome scores for each group at each time bracket were not normally 
distributed. In addition, the number of scores in the African American population was 
fewer than that required for the Central Limit Theorem to apply (n=30) for the use of 
parametric statistics. Therefore, a nonparametric statistical procedure, the Kruskal-Wallis 
test was used to evaluate the differences between gender and racial groups for the QoL 
outcome scores at each time bracket post transplantation. A p-value of.05 was set for 
statistical significance. 
 
 
Differences in SF-12 Scores by Racial and Gender Groups 
 
No differences were found between MCS mean ranks for the demographic groups 
at any of the four time brackets (Table 4.1).  Similarly, no differences were found 
between the mean ranked PCS scores at less than 4 months, 4 months to18 months or 
greater than 36 months. However, a significant difference between the mean ranked PCS 
scores was seen at 19 months to 36 months post transplantation (p=.047), where the mean 
Table 4.1.  Kruskal-Wallis Ranks and Test Statistics for Differences in MCS Scores 
between Demographic Groups at <4 Months, 4-18 Months, 19-36 Months and >36 
Months Post-Transplantation. 
 
 
 
 
<4 months 
 
4-18 months 19-36 months >36 months 
 
Racial/Gender 
Group 
N Mean Rank N 
Mean 
Rank N 
Mean 
Rank N 
Mean 
Rank 
 
Caucasian 
Male 
94 108.64 94 119.21 89 98.99 90 102.41 
 
Caucasian 
Female 
66 106.32 86 113.19 82 108.67 83 99.64 
 
African 
American 
Male 
21 112.19 16 90.78 14 109.71 12 124.29 
 
African 
American 
Female 
30 92.68 30 108.60 22 103.23 18 96.00 
 
 χ2 =1.821 χ2 =2.820 χ2 =1.253 χ2 =2.054 
 df=3 df=3 df=3 df=3 
 p=.610 p=.420 p=.740 p=.561 
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rank of African American women (92.68) was lower than that of Caucasian men 
(108.64), Caucasian women (106.32), or African American men (112.19) (Table 4. 2). 
Figures 4.1 and 4.2 illustrate the mean MCS and PCS scores by demographic group. 
There were minimal differences in the actual mean scores between the groups across the 
time brackets and although the Kruskal-Wallis Test found a statistical difference in PCS 
scores, the actual scores are closely grouped. 
 
 
Differences in Memphis Survey Scores by Racial and Gender Groups 
 
Memphis Survey Frequency mean rank scores were only found to differ at less 
than 4 months post transplantation (p=.021) with African American men reporting better 
QoL (lower scores) as it relates to the frequency of immunosuppressant side effects 
(Table 4.3).  No differences were found between mean ranks of the Memphis Survey 
Severity scores (Table 4.4).  Bar graphs for the means of both Memphis Survey scores 
also illustrate, that scores are very closely grouped (Figures 4.3 and 4.4).  
 
 
Construction of Time-Related Centile Ranges 
 
The Kruskal-Wallis analyses demonstrated a strong degree of homogeneity 
among racial and gender specific demographic groups with only 2 of 16 QoL outcome 
measures found to be significantly different.  The two scores that differed were from 
different instruments (PCS from the SF-12 and Memphis Survey Frequency) and were 
from different time periods (19 months to 36 months for the PCS and less than 4 months 
for the Memphis Survey Frequency). Moreover, the variation in the means across the 
groups was small (PCS at 19 months to 36 months means ranged from 38.15 to 45.99 on 
a 100 point scale; Memphis Frequency at less than 4 months means ranged from 32.98 to 
49.63 on an 160 point scale) leading to the conclusion that negligible clinical differences 
exist for the QoL outcomes for racial and gender subgroups regardless of the finding that 
two of the scores differed statistically.  Therefore, only one time-related centile range was 
required to adequately represent the QoL outcomes for this cohort of kidney transplant 
recipients. 
 
The time-related centile ranges for PCS scores, MCS scores, Memphis Survey 
Frequency Scores, and Memphis Survey Severity Scores are pictured in Figures 4.5 and 
4.6. The design for the time-related centile range enables assessment of QoL of an 
individual at four separate time brackets following transplantation.  Subscales of the SF-
12 and Memphis Survey are depicted on the same page for ease of use and comparison. 
Better QoL is indicated by higher scores on the SF-12 but by lower scores on the 
Memphis Survey; therefore the y-axis of the Memphis Survey centile ranges has been 
inverted for consistency in visualization of the scores. The darker shading on each bar 
corresponds to improved QoL scores. 
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Table 4.2.  Kruskal-Wallis Ranks and Test Statistics for Differences in PCS Scores 
between Demographic Groups at <4 Months, 4-18 Months, 19-36 Months and >36 
Months Post-Transplantation. 
 
 
 
<4 months 
 
4-18 months 19-36 months >36 months 
 
Racial/Gender 
Group 
N Mean Rank N 
Mean 
Rank N 
Mean 
Rank N 
Mean 
Rank 
 
Caucasian 
Male 
94 104.44 94 111.99 89 106.72 90 102.03 
 
Caucasian 
Female 
66 104.97 86 124.48 82 111.74 83 105.57 
 
African 
American 
Male 
21 121.67 16 92.72 14 87.93 12 119.96 
 
African 
American 
Female 
30 102.18 30 97.83 22 74.36 18 73.42 
         
 χ2=1.580 χ2=5.815 χ2=7.948 χ2=5.689 
 df=3 df=3 df=3 df=3 
 p=.664 p=.121 p=.047 p=.128 
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Figure 4.1.  Mean MCS Scores for Demographic Groups by Time Since Transplantation. 
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Figure 4.2.  Mean PCS Scores for Demographic Groups by Time Since Transplantation. 
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Table 4.3.  Kruskal-Wallis Ranks and Test Statistics for Differences in Memphis Survey 
Frequency Scores between Demographic Groups at <4 Months, 4-18 Months, 19-36 
Months and >36 Months Post-Transplantation. 
 
 
 
 
<4 months 
 
4-18 months 19-36 months >36 months 
 
Racial/Gender 
Group 
N Mean Rank N 
Mean 
Rank N 
Mean 
Rank N 
Mean 
Rank 
 
Caucasian 
Male 
75 89.66 78 96.26 70 82.53 93 104.10 
 
Caucasian 
Female 
49 107.37 65 98.40 65 90.35 88 113.09 
 
African 
American 
Male 
27 68.85 19 95.11 16 83.88 15 70.73 
 
African 
American 
Female 
34 98.84 33 102.98 22 93.59 16 117.75 
         
 χ2=9.714 χ2=.385 χ2=1.293 χ2=6.796 
 df=3 df=3 df=3 df=3 
 p=.021 p=.943 p=.731 p=.079 
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Table 4.4.  Kruskal-Wallis Ranks and Test Statistics for Differences in Memphis Survey 
Severity Scores between Demographic Groups at <4 Months, 4-18 Months, 19-36 
Months and >36 Months Post-Transplantation. 
 
  
<4 months 
 
4-18 months 19-36 months >36 months 
 
Racial/Gender 
Group 
N Mean Rank N 
Mean 
Rank N 
Mean 
Rank N 
Mean 
Rank 
 
Caucasian 
Male 
71 82.68 77 97.49 65 79.75 90 98.82 
 
Caucasian 
Female 
46 97.78 64 97.88 63 86.28 88 113.65 
 
African 
American 
Male 
24 66.42 19 83.13 16 79.00 15 74.57 
 
African 
American 
Female 
29 88.72 32 99.28 20 82.35 13 100.62 
         
 χ2=6.831 χ2=1.244 χ2=.704 χ2=6.670 
 df=3 df=3 df=3 df=3 
 p=.077 p=.742 p=.872 p=.083 
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Figure 4.3.  Mean Memphis Survey Frequency Scores for Demographic Groups by Time 
Since Transplantation. 
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Figure 4.4.  Mean Memphis Survey Severity Scores for Demographic Groups by Time 
Since Transplantation. 
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Figure 4.5.  Time-Related Centile Range for Kidney Transplantation Recipients:  SF-12 Health Survey. 
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Figure 4.6.  Time-Related Centile Range for Kidney Transplantation Recipients:  Memphis Survey. 
Discussion 
 
QoL life measurements such as those provided by the SF-12 and the Memphis 
Survey are rarely used in the clinical setting to assess individual patients and no studies 
have reported routine use in the kidney transplantation setting of any QoL outcome 
measure. A number of reasons have been discussed as to why QoL outcomes are not used 
in the clinical setting in spite of the importance placed on QoL (Higginson & Carr, 2001, 
Greenhalgh, Long, &  Flynn, 2005). Perhaps the most common reason is the perceived 
time spent completing questionnaires that subsequently provide information that is 
difficult to interpret and is perceived to offer little insight into an individual patient’s 
status. The SF-12 and Memphis Survey are self-administered questionnaires that most 
patients can complete without assistance in a short period of time prior to the clinic visit. 
The time-related centile ranges place the scores in a context that can be easily interpreted 
for patients as they compare their score with others and monitor their progress over time.   
 
Espallagues, Valderas, and Alonso (2000), examined the influence the use of 
health status measures had on clinical decision making and improvement in patient 
outcomes. Although, the assessment of QoL did not have a direct influence on patient 
outcomes or clinical decision making, this review concluded that using health status or 
QoL measures modified the process of patient care. Greenhalgh, Long, & Flynn (2005) 
support this conclusion suggesting that studies may not be asking the correct question in 
evaluating the utility of patient outcomes in clinical practice and instead argue for a 
theory driven approach to evaluation of the use of QoL measurement tools for patient 
assessment that focuses on the process as well as the effect of QoL measures on decision 
making or clinical outcomes.  For example, QoL assessment has been used in the 
oncology setting with beneficial results, not in patient outcomes per se but rather in 
increased communication and heightened provider awareness of the patient’s QoL 
(Detmar et al., 2002). Velikova et al. (2004) likewise found that routine assessment of 
QoL of oncology patients enhanced patient-provider communication and in addition 
correlated with improved QoL and emotional functioning. The time-related centile ranges 
presented in this study for kidney transplant recipients would facilitate interpretation of 
QoL scores, facilitate routine assessment of QoL outcomes, enhance discussions with 
patients regarding their Qol outcomes, identify patients who would benefit from 
interventions designed to improve QoL outcomes, and help or to reassure those patients 
who are doing well. 
 
The SF-12 has been used to estimate QoL for the general population. Mean scores 
for the general population reported for the PCS and MCS score respectively are 49.6 and 
52.0 (Johnson & Coons, 1998). Hathaway, et al. (2003b) reported the range of scores for 
the US general population from 13-69 for the PCS and 10-70 on the MCS. Mean score 
for this sample for PCS and MCS scores were 42.39 (range 6 to 65) and 50.11 (range 10 
to 71) respectively. The mean and range of the MCS scores in this sample are comparable 
to the general population. However, the PCS scores are were lower when compared to the 
general population. This is consistent with early data reported from the PORTEL registry 
and indicates impaired physical QoL following kidney transplantation (Hathaway, et al. 
2003b). 
 55 
 
Time-related centile ranges are useful if the sample used for construction of the 
range is representative of the population for which it is designed. The sample for this 
study was drawn from a multi-institutional study with participants recruited from 
different regions of the country. Since the participants were from diverse areas and 
diverse transplantation centers, the ranges have greater generalizability than a sample 
drawn from a single site.  
 
The gender and racial distribution in this sample was compared to the distribution 
reported in the United Network for Organ Sharing (UNOS) data base which represents all 
transplant recipients. A significant difference was found between the UNOS data and the 
PORTEL sample (χ2=25.03, p<.01). The percentage of Caucasian females in the study 
sample was slightly higher than that reported in the UNOS database, 35.7% and 28.52% 
respectively. This difference is likely to be of little clinical significance. African 
American males, however, comprised only 9.5% of the study sample compared with 
16.24% reported by UNOS. As a result application of the time-related centile ranges in 
the African-American male population should be done cautiously and the ranges used 
more as a means to monitor patient progress as opposed to comparison with an 
established “norm”. Even so, the width of the individual centile ranges is such that if the 
sample of African American males used in this study was different from the larger 
population of African American male kidney transplant recipients, the impact of this 
difference on the centile ranges and ultimate clinical use would be minimal. 
 
African American and Causcasians were specifically targeted for this first effort 
at establishing QoL centile ranges based on available data. Additional QoL data will be 
required before centile ranges can be constructed or specific recommendations can be 
made for use in other ethnic groups. Patients who have undergone more than one kidney 
transplantation are also not represented in these time-related centile ranges. Just as using 
QoL outcome measure has potential utility for kidney transplant recipients, recipients of 
other solid organ transplantations may also benefit from QoL benchmarks to interpret 
QoL outcome scores. The sample size required for development of time-related centile 
ranges for other solid organ transplantation recipients may make development of the 
ranges more challenging. 
 
The PORTEL registry recruited participants from a variety of patient and site centric 
venues. During the first half of the data collection period, participants were recruited 
from transplantation centers, national transplantation meetings, community events, 
support groups, and direct mail. This methodology had the potential to select a healthier 
population that might not be fully representative of QoL following transplantation. 
During the later data collection period recruitment was limited to referrals from 
transplantation centers in order to create a more representative sample. 
 
The time-related centile ranges constructed in this study do not account for patient 
age which has been shown to be a factor in QoL post transplantation (Baiardi et al., 2002; 
Fujisawa et al., 2000). The current sample includes transplant recipients between the ages 
of 18 and 65, chosen to represent the working age adult. The decision to include all adults 
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in the single time-related centile range was based primarily on the age distribution of the 
participants in the sample.   
 
 
Conclusion 
 
The centile ranges constructed in this study have immediate clinical utility as a 
tool for educating patients regarding expectations prior to transplantation and for 
monitoring progress over time post transplantation. They can provide a means for 
transplant recipients to compare their QoL to a reference range derived from a like 
population as opposed to the general population and will serve as a catalyst for discussion 
regarding interventions to enhance QoL.  
 
The outcomes of this project also have application in the research arena as well. 
QoL and changes in QoL will continue to be a variable of interest to researchers as the 
kidney transplantation population ages. The outcomes of this study will provide 
additional baseline data for future QoL research and can provide benchmarks for 
evaluating interventions designed to improve QoL.  
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Appendix A: Descriptive Statistics for Quality of Life Outcome Measures by  
Racial and Gender Groups for Time Intervals Following Transplantation 
 
Descriptive statistics, including the mean and median scores, standard deviation, 
and range of the four QoL outcome variables for the 4 demographic groups (Caucasian 
male, Caucasian Female, African American Male, and African American Female) at each 
time interval post transplantation and bar graphs of the 50th percentile scores for each 
outcome are provided in this appendix.
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Table A.1.  Descriptive Statistics for the MCS Scores by Racial and Gender Groups for 
Time Intervals Following Transplantation. 
  
 N Mean Median Range Standard Deviation 
4-18 months   
    
 
Caucasian Male 
 
94 
 
51.71 
 
53.21 
 
52.07 
 
10.34 
Caucasian Female 66 51.42 53.35 49.38 9.98 
African American 
Male 21 52.99 52.04 27.36 7.46 
African American 
Female 30 50.10 50.22 31.74 8.30 
4-18 months   
    
 
Caucasian Male 
 
94 
 
54.45 
 
54.78 
 
52.95 
 
11 
Caucasian Female 86 50.74 54.15 50.87 10.46 
African American        
Male 16 47.41 44.57 30.55 10.09 
African American 
Female 30 50.52 51.08 33.27 9.58 
19-36 months   
    
 
Caucasian Male 
 
89 
 
48.33 
 
50.04 
 
45.88 
 
10.78 
Caucasian Female 82 49.84 51.54 54.97 10.62 
African American 
Male 14 50.53 53.88 34.39 10.74 
African American 
Female 22 49.53 49.36 25.55 8.64 
>36 months   
    
 
Caucasian Male 
 
90 
 
48.34 
 
50.28 
 
58.22 
 
11.68 
Caucasian Female 83 48.28 51.46 47.98 10.87 
African American 
Male 12 51.15 56.14 42.91 13.15 
African American  
Female 18 47.67 48.43 34.95 11.30 
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Figure A.1.  50th Percentile, MCS Scores for Demographic Groups by Time Since 
Transplantation 
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Table A.2.  Descriptive Statistics for the PCS Scores by Racial and Gender Groups for 
Time Intervals Following Transplantation. 
 
 N Mean Median Range Standard Deviation 
<4 months      
 
 
Caucasian Male 
 
94 
 
36.06 
 
36.02 
 
46.01 
 
11.3 
Caucasian Female 66 36.59 34 47.15 11.66 
African American 
Male 21 39.20 40.36 38.33 10.95 
African American 
Female 30 36.27 34.47 45.07 11.32 
4-18 months   
    
 
Caucasian Male 
 
94 
 
44.09 
 
45.71 
 
59.29 
 
12.15 
Caucasian Female 86 46.07 47.96 54.24 12.5 
African American 
Male 16 41.77 40.36 32.5 9.43 
African American 
Female 30 41.38 43.04 47.09 13.13 
19-36 months   
    
 
Caucasian Male 
 
89 
 
44.83 
 
47.98 
 
51.62 
 
13.05 
Caucasian Female 82 45.99 50.15 52.34 12.7 
African American 
Male 14 40.94 41.13 42.9 13.48 
African American 
Female 22 38.15 38.42 44.96 13.1 
>36 months   
    
 
Caucasian Male 
 
90 
 
44.36 
 
48.46 
 
45.23 
 
12.34 
Caucasian Female 83 44.79 47.9 52.98 12.15 
African American 
Male 12 48.08 48.32 38.29 11 
African American 
Female 18 39.43 39.72 36.45 9.47 
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Figure A.2.  50th Percentile, PCS Scores for Demographic Groups by Time Since 
Transplantation. 
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Table A.3.  Descriptive Statistics for the Memphis Survey Frequency Scores by Racial 
and Gender Groups for Time Intervals Following Transplantation.  
 
 N Mean Median Range Standard Deviation 
<4 months      
 
 
Caucasian Male 
 
75 
 
43.52 
 
40.93 
 
111.97 
 
25.91 
Caucasian Female 49 49.63 50.5 96.96 22.92 
African American 
Male 27 32.98 27.58 85.84 23.2 
African American 
Female 34 45.75 43.92 70.16 20 
4-18 months   
    
 
Caucasian Male 
 
78 
 
49.93 
 
45.13 
 
131.36 
 
29.64 
Caucasian Female 65 52.1 46.61 132.62 31.86 
African American 
Male 19 48 42.38 80.60 21.15 
African American 
Female 33 52.2 50 92.00 23.21 
19-36 months   
    
 
Caucasian Male 
 
70 
 
53.81 
 
45.67 
 
133.46 
 
33.47 
Caucasian Female 65 59.29 57.97 142.14 35.04 
African American 
Male 16 52.31 43. 82.84 23 
African American 
Female 22 59.5 60.15 100.14 27.87 
>36 months   
    
 
Caucasian Male 
 
93 
 
59.08 
 
57.36 
 
167.73 
 
35.82 
Caucasian Female 88 64.28 59.1 168.51 34.33 
African American 
Male 15 44.09 36.33 147.86 40.73 
African American 
Female 16 64.56 67.24 88.51 27.82 
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Figure A.3.  50th Percentile, Memphis Survey Frequency Scores for Demographic Groups 
by Time Since Transplantation. 
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Table A.4.  Descriptive Statistics for the Memphis Survey Severity Scores by Racial and 
Gender Groups for Time Intervals Following Transplantation. 
  
 N Mean Median Range Standard Deviation 
<4 months       
 
Caucasian Male 
 
71 
 
35.32 
 
29.83 
 
29.83 
 
27.6 
Caucasian Female 46 41.53 42.73 106.75 25.23 
African American 
Male 24 26.59 15.42 83.12 24.38 
African American 
Female 29 35.28 32.94 69.18 19.28 
4-18 months   
    
 
Caucasian Male 
 
77 
 
45.37 
 
41.38 
 
133.18 
 
30.91 
Caucasian Female 64 48.03 38 135.17 36.33 
African American 
Male 19 36.66 34.55 98.57 25.41 
African American 
Female 32 45.18 38.73 109.33 26.74 
19-36 months   
    
 
Caucasian Male 
 
65 
 
46.67 
 
40.3 
 
113.28 
 
33.68 
Caucasian Female 63 52.53 49.46 132.21 37.15 
African American 
Male 16 44 32.55 82.90 25.54 
African American 
Female 
 
20 47.03 40.95 116.75 31.83 
>36 months   
    
 
Caucasian Male 
 
90 
 
52.92 
 
43.31 
 
183.64 
 
41.7 
Caucasian Female 88 59.95 53.64 172.14 37.15 
African American 
Male 15 40.46 27.81 149.68 43.54 
African American 
Female 13 47.21 58.25 68.61 23.27 
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Figure A.4.  50th Percentile, Memphis Survey Severity Scores for Demographic Groups 
by Time Since Transplantation.
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Appendix B: Memphis Survey Subscales 
 
The Memphis Survey was developed at the University of Tennessee Health 
Science to assess frequency and severity of side effect from immunosuppressant 
medications. The survey consists of 5 subscales to evaluate the areas that have been 
reported to be most problematic for transplant recipients. The subscale scores are totaled 
to provide a cumulative score for frequency and severity of side effects of 
immunosuppressant therapy. Descriptive statistics for the subscales were reviewed for the 
sample as a whole with all time groups combined by the racial and gender specific 
demographic groups, Caucasian men, Caucasian women, African-American men and 
African-American women. The means and ranges for the subscale scores were similar 
(Tables B.1 and B.2) and were represented in the total frequency and severity scores. The 
study aim was to design time-related centile ranges that would be useful in clinical 
practice. Separate ranges for the 5 subscales which would be very similar to each other 
and to the range for the total scores would be more unwieldy to implement in practice and 
contribute little additional information. As a result the decision was made include only 
the cumulative Memphis Survey frequency and severity scores in the analysis for this 
study.
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Table B.1.  Descriptive Statistics for the Memphis Survey Frequency Subscale Scores. 
 
Subscale Racial-Gender Group N Mean 
Standard 
Deviation Min Max 
 
Caucasian Male 395 10.38 8.50 0.00 40.00 
Caucasian Female 336 10.66 8.34 0.00 39.09 
African-American 
Male 78 7.45 6.19 0.00 28.18 
African-American 
Female 108 10.33 6.82 0.00 25.45 
 
Emotional 
Burden 
  
  
  
Total 917 10.23 8.12 0.00 40.00 
 
Caucasian Male 388 9.49 9.08 0.00 39.09 
Caucasian Female 335 9.45 9.47 0.00 40.00 
African-American 
Male 78 8.1 9.19 0.00 36.36 
African-American 
Female 106 9.95 8.45 0.00 34.55 
 
Life/Role 
Responsibility 
 
  
  
  
Total 907 9.41 9.16 0.00 40.00 
 
Caucasian Male 394 7.15 6.67 0.00 28.33 
Caucasian Female 338 9.21 7.27 0.00 35.00 
African-American 
Male 77 7.03 6.06 0.00 28.33 
African-American 
Female 109 8.36 6.18 0.00 26.27 
 
GI distress 
 
  
  
Total 918 8.04 6.86 0.00 35.00 
 
Caucasian Male 327 12.94 6.83 0.00 37.27 
Caucasian Female 270 14.50 6.97 0.00 32.73 
African-American 
Male 78 10.16 6.02 0.00 25.45 
African-American 
Female 110 11.67 5.58 0.00 25.45 
 
Mobility 
  
  
  
  
Total 785 13.02 6.77 0.00 37.27 
 
Caucasian Male 
 
393 
 
11.86 
 
9.89 
 
0.00 
 
40.00 
Caucasian Female 338 13.13 10.59 0.00 40.00 
African-American 
Male 78 9.87 8.64 0.00 40.00 
African-American 
Female 109 13.25 8.96 0.00 38.57 
 
Miscellaneous 
  
  
  
Total 918 12.33 9.98 0.00 40.00 
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Table B.2.  Descriptive Statistics for the Memphis Survey Severity Subscale Scores. 
 
Subscale Racial-Gender Group N Mean 
Standard 
Deviation Min Max 
 
Caucasian Male 390 9.33 9.14 0.00 40.00 
Caucasian Female 335 9.74 9.05 0.00 40.00 
African-American 
Male 77 5.75 6.55 0.00 28.18 
African-American 
Female 103 7.73 7.11 0.00 32.73 
 
Emotional 
Burden 
  
  
  
Total 905 9.00 8.76 0.00 40.00 
 
Caucasian Male 382 8.08 8.71 0.00 40.00 
Caucasian Female 332 8.51 9.38 0.00 40.00 
African-American 
Male 77 6.59 9.05 0.00 36.36 
African-American 
Female 101 7.06 7.44 0.00 28.18 
 
Life/Role 
Responsibility 
 
  
  
  
Total 892 8.00 8.87 0.00 40.00 
 
Caucasian Male 389 6.31 7.24 0.00 30.00 
Caucasian Female 333 8.18 7.73 0.00 35.00 
African-American 
Male 76 6.05 6.19 0.00 28.33 
African-American 
Female 105 6.49 5.74 0.00 21.67 
 
GI distress 
 
  
  
Total 903 7.00 7.24 0.00 35.00 
 
Caucasian Male 388 11.16 10.31 0.00 40.00 
Caucasian Female 334 12.63 11.25 0.00 40.00 
African-American 
Male 77 90.5 8.91 0.00 40.00 
African-American 
Female 101 11.71 9.63 0.00 38.57 
 
Mobility 
  
  
  
  
Total 900 11.59 10.52 0.00 40.00 
 
Caucasian Male 318 10.36 7.21 0.00 36.36 
Caucasian Female 268 12.37 7.61 0.00 32.73 
African-American 
Male 77 7.49 6.16 0.00 27.27 
African-American 
Female 105 8.95 6.45 0.00 32.73 
 
Miscellaneous 
  
  
  
Total 768 10.58 7.32 0.00 36.36 
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